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Abstract Protein kinases are major drug targets, but the development of highly-selective
inhibitors has been challenging due to the similarity of their active sites. The observation of distinct
structural states of the fully-conserved Asp-Phe-Gly (DFG) loop has put the concept of
conformational selection for the DFG-state at the center of kinase drug discovery. Recently, it was
shown that Gleevec selectivity for the Tyr-kinase Abl was instead rooted in conformational changes
after drug binding. Here, we investigate whether protein dynamics after binding is a more general
paradigm for drug selectivity by characterizing the binding of several approved drugs to the Ser/
Thr-kinase Aurora A. Using a combination of biophysical techniques, we propose a universal drug-
binding mechanism, that rationalizes selectivity, affinity and long on-target residence time for
kinase inhibitors. These new concepts, where protein dynamics in the drug-bound state plays the
crucial role, can be applied to inhibitor design of targets outside the kinome.
DOI: https://doi.org/10.7554/eLife.36656.001
Introduction
Protein kinases have become the number one drug target of the 21th century (Cohen, 2002;
Hopkins and Groom, 2002), due to their central role in cellular processes and involvement in various
types of cancer (Carvajal et al., 2006; Gautschi et al., 2008; Katayama and Sen, 2010). Despite
their therapeutic significance, the development of specific kinase inhibitors proves to be extremely
challenging because they must discriminate between the very similar active sites of a large number
of kinases in human cells. One of the biggest success stories is Gleevec: a highly selective drug that
specifically targets Abl kinase, providing an efficient treatment of chronic myelogenous leukemia
(CML) and minimizing side effects (Iqbal and Iqbal, 2014). Despite being a multi-billion-dollar cancer
drug, the mechanism responsible for its impressive selectivity has been elusive until recently. Seminal
work by the Kuriyan lab demonstrated that Gleevec can only bind to an inactive DFG (for Asp-Phe-
Gly) loop conformation in the ‘out-conformation’ due to steric clash of the active, DFG-in conforma-
tion (Nagar et al., 2002; Schindler et al., 2000; Seeliger et al., 2007). Since then it has long been
proposed that the conformational state of the fully-conserved DFG loop (Taylor et al., 2012) dic-
tates the selectivity for Gleevec and other kinase inhibitors (Lovera et al., 2012; Nagar et al., 2002;
Schindler et al., 2000; Treiber and Shah, 2013; Xu et al., 1997). The orientation of the DFG-motif
and its possible steric clashes is indeed important for the ability of a class of inhibitors to bind to the
kinase, but proved insufficient to explain drug selectivity and affinity. Earlier elegant work on Src and
Abl recognized this and explored other hypotheses (e.g., differences in drug-binding pocket, ener-
getic changes remote from the binding site and a conformational-selection mechanism) to reconcile
the differences in Gleevec binding (Dar et al., 2008; Levinson et al., 2006; Seeliger et al., 2007;
2009), but without conclusive success. Recent quantitative binding kinetics combined with ancestral
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sequence reconstruction put forward a mechanism where an induced-fit step after drug binding is
the key determinant for Gleevec’s selectivity (Agafonov et al., 2014; Wilson et al., 2015), and fully
recapitulates the binding affinities.
Here we ask the question whether this fundamentally different mechanism is a more general prin-
ciple for drug efficacy and selectivity not only for Tyr kinases such as Abl, but also for Ser/Thr kin-
ases. To this end, we chose the Ser/Thr kinase Aurora A and investigated the binding kinetics of
three distinct kinase drugs: Danusertib, AT9283, and Gleevec. Aurora A kinase is one of the key reg-
ulators of mitotic events, including mitotic entry, centrosome maturation and spindle formation
(Fu et al., 2007; Lukasiewicz and Lingle, 2009; Marumoto et al., 2005), as well as assisting in neu-
ronal migration (Nikonova et al., 2013). Aurora A has attracted significant attention for the develop-
ment of targeted agents for cancer because it is overexpressed in a wide range of tumors, including
breast, colon, ovary and skin malignancies (Carvajal et al., 2006; Gautschi et al., 2008;
Katayama and Sen, 2010; Lok et al., 2010; Marzo and Naval, 2013). The focus was mainly on
ATP-competitive inhibitors, but more recently inhibition by allosteric compounds has also been pur-
sued with the aim of achieving higher selectivity (Asteriti et al., 2017; Bayliss et al., 2017;
Burgess et al., 2016; Janecˇek et al., 2016; McIntyre et al., 2017). So far, only the clinical signifi-
cance of Aurora A inhibition by ATP-competitive drugs has been established (Bavetsias and Linar-
dopoulos, 2015; Borisa and Bhatt, 2017), but little is known about their binding mechanisms. Many
high-resolution X-ray structures of Aurora A kinase bound to different inhibitors have been solved
(Bavetsias et al., 2015; Dodson et al., 2010; Fancelli et al., 2006; Ferguson et al., 2017;
Heron et al., 2006; Howard et al., 2009; Kilchmann et al., 2016; Martin et al., 2012; Zhao et al.,
2008), but the selectivity profile of those kinase inhibitors remains very difficult to explain.
eLife digest Protein kinases are a family of enzymes found in all living organisms. These
enzymes help to control many biological processes, including cell division. When particular protein
kinases do not work correctly, cells may start to divide uncontrollably, which can lead to cancer. One
example is the kinase Aurora A, which is over-active in many common human cancers. As a result,
researchers are currently trying to design drugs that reduce the activity of Aurora A in the hope that
these could form new anticancer treatments.
In general, drugs are designed to be as specific in their action as possible to reduce the risk of
harmful side effects to the patient. Designing a drug that affects a single protein kinase, however, is
difficult because there are hundreds of different kinases in the body, all with similar structures.
Because drugs often work by binding to specific structural features, a drug that targets one protein
kinase can often alter the activity of a large number of others too.
Gleevec is a successful anti-leukemia drug that specifically works on one target kinase, producing
minimal side effects. It was recently discovered that the drug works through a phenomenon called
‘induced fit’. This means that after the drug binds it causes a change in the enzyme’s overall shape
that alters the activity of the enzyme. The shape change is complex, and so even small structural
differences can change the effect of a particular drug.
Do other drugs that target other protein kinases also produce induced fit effects? To find out,
Pitsawong, Buosi, Otten, Agafonov et al. studied how three anti-cancer drugs interact with Aurora
A: two drugs specifically designed to switch off Aurora A, and Gleevec (which does not target
Aurora A).
The two drugs that specifically target Aurora A were thought to work by targeting one structural
feature of the enzyme. However, the biochemical and biophysical experiments performed by
Pitsawong et al. revealed that these drugs instead work through an induced fit effect. By contrast,
Gleevec did not trigger an induced fit on Aurora A and so bound less tightly to it.
In light of these results, Pitsawong et al. suggest that future efforts to design drugs that target
protein kinases should focus on exploiting the induced fit process. This will require more research
into the structure of particular kinases.
DOI: https://doi.org/10.7554/eLife.36656.002
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The drugs used in this study are small, ATP-competitive inhibitors. Danusertib (PHA739358) and
AT9283 were developed for Aurora kinases, whereas Gleevec is selective for the Tyr kinase Abl. Dan-
usertib inhibits all members of the Aurora family with low nanomolar IC50 values (13, 79 and 61 nM
for Aurora A, B and C, respectively) (Carpinelli et al., 2007; Fraedrich et al., 2012) and was one of
the first Aurora kinase inhibitors to enter phase I and II clinical trials (Kollareddy et al., 2012;
Steeghs et al., 2009). A crystal structure of Danusertib bound to Aurora A kinase shows an inactive
kinase with the DFG-loop in the out conformation (Fancelli et al., 2006). AT9283 inhibits both
Aurora A and B with an IC50 of 3 nM (Howard et al., 2009) and has also entered several clinical trials
(Borisa and Bhatt, 2017). Interestingly, the crystal structure of Aurora A with AT9283 shows that
this drug binds to the DFG-in, active conformation of the kinase (Howard et al., 2009). Both drugs
are high-affinity binders that reportedly bind to a discrete kinase conformation and would allow us
to probe for a conformational-selection step. Lastly, we selected Gleevec as a drug that is not selec-
tive for Aurora A and should, therefore, have a weaker binding affinity. We reasoned that this choice
of inhibitors could reveal general mechanisms underlying drug selectivity and affinity.
The combination of X-ray crystallography, NMR spectroscopy and comprehensive analysis of drug
binding and release kinetics delivered a general mechanistic view. Differential drug affinity is not
rooted in the overwhelmingly favored paradigm of the DFG-conformation, but instead in the
dynamic personality of the kinase that is manifested in conformational changes after drug binding.
Notably, such conformational changes have evolved for its natural substrates, and the drugs take
advantage of this built-in protein dynamics.
Results
Dephosphorylated Aurora A samples both an inactive and active
structure
A plethora of X-ray structures and functional assays led to the general notion that dephosphorylated
Aurora A and, more universally, Ser/Thr kinases are in an inactive conformation and that phosphory-
lation or activator binding induces the active structure. A comparison of many X-ray structures of
inactive and active forms of Ser/Thr kinases resulted in an elegant proposal of the structural hall-
marks for the active state by Taylor and collaborators: the completion of both the regulatory and
catalytic spines spanning the N- and C-terminal domains, including the orientation of the DFG-motif
(Kornev and Taylor, 2010; 2015). X-ray structures, however, provide merely static snapshots of pos-
sible kinase conformations that do not necessarily reflect the situation in solution. In fact, recent
experimental data postulate that phosphorylation of Aurora A does not ‘lock’ the kinase in the active
conformation, and that the activation-loop still exhibits conformational dynamics (Gilburt et al.,
2017; Ruff et al., 2018). On the other hand, X-ray crystallography provides high-resolution structural
data that cannot readily be obtained from FRET or EPR and IR spectroscopy.
Two crystals from the same crystallization well capture both the inactive and active conformations
of dephosphorylated Aurora A bound with AMPPCP (Figure 1A,B). As anticipated, the first structure
(PDB 4C3R [Zorba et al., 2014]) superimposes with the well-known inactive, dephosphorylated
Aurora A structure (PDB 1MUO [Cheetham et al., 2002]) and the activation loop is not visible as
commonly observed for kinases lacking phosphorylation of the activation loop (Zorba et al., 2014).
The second structure (PDB 6CPF; Table 1) adopts the same conformation as the previously pub-
lished phosphorylated, active structure (PDB 1OL7 [Bayliss et al., 2003]) (Figure 1C) and the first
part of the activation loop could be built, although the B-factors are high. Every hallmark of an active
state is seen for this dephosphorylated protein, including the DFG-in conformation that is essential
for completing the regulatory spine. In contrast, the DFG-loop is in the out position for the inactive
form of Aurora A (Figure 1D, cyan). In the active, non-phosphorylated structure, electron density is
seen in the canonical tighter Mg2+-binding site, where the metal ion is coordinated to the a- and b-
phosphates of AMPPCP and Asp274. The presence of the metal is supported by the CheckMyMetal
(Zheng et al., 2017) validation, except that the coordination is incomplete. We surmise that two
water molecules, not visible in our data, complete the coordination sphere as is seen in several
higher-resolution structures. In the inactive structure, no electron density for Mg2+ can be identified
possibly due to the fact that Asp274 is rotated to the DFG-out position and is, therefore, lost as
coordination partner. Furthermore, sampling of the active conformation does not depend on
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AMPPCP binding as dephosphorylated, apo Aurora A also crystallizes in the active form (PDB 6CPE;
Figure 1E,F and Table 1). Our results are consistent with other crystallographic studies on wild-
type, dephosphorylated Aurora A in its apo or nucleotide bound state, where the kinase was also
found in the active conformation (Gustafson et al., 2014; Janecˇek et al., 2016; Nowakowski et al.,
2002).
We note that in Aurora kinase sequences a tryptophan residue, Trp277, is immediately following
the DFG motif and displays a drastically different orientation whether Aurora A is in an active (DFG-
in) or inactive (DFG-out) conformation (Figure 1D). This Trp moiety is unique for the Aurora kinase
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Figure 1. Dephosphorylated Aurora A samples both the active and inactive conformation. (A) Superposition of X-ray structures of dephosphorylated
Aurora A (residues 122–403) with Mg2+AMPPCP (AMPPCP in gray sticks and magnesium as yellow sphere) in the inactive (cyan, PDB 4C3R
[Zorba et al., 2014]) and active (orange, PDB 6CPF) state, solved from crystals of the same crystallization well. (B) Zoom-in of (A) to visualize the
nucleotide binding region (K162, D274, and E181), the R-spine (L196, Q185, F275, H254, and D311) and the activation loop region (D256, K258, and
T292). (C) Same zoom-in as in (B), but dephosphorylated Aurora A in active state (orange) is superimposed with phosphorylated Aurora A (red, PDB
1OL7 [Bayliss et al., 2003]). (D) Superposition of the DFG(W) motif in the three states shown in (B) and (C). (E) Superposition of phosphorylated Aurora
A in active conformation (red) and apo, dephosphorylated Aurora A also in the active conformation (yellow, PDB 6CPE). (F) Zoom-in of (E) showing the
same region as in (B).
DOI: https://doi.org/10.7554/eLife.36656.003
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family in the Ser/Thr kinome and its position is suggested to be important for tuning the substrate
specificity (Chen et al., 2014). We used this Trp residue as probe to monitor the DFG flip and drug
binding in real time as described below.
The fact that the inactive and active states are seen in the crystal implies that both are sampled;
however, it does not deliver information about the relative populations or interconversion rates.
Therefore, we set out to monitor the conformational exchange of the DFG-in/out flip in solution.
Owing to the reported importance of the DFG flip for activity, regulation and drug design, there
have been extensive efforts to characterize this conformational equilibrium by computation
(Badrinarayan and Sastry, 2014; Barakat et al., 2013; Meng et al., 2015; 2017; Sarvagalla and
Coumar, 2015; Shukla et al., 2014). The general notion of these computational studies is that in the
absence of phosphorylation the inactive form of the kinase is most favored, in agreement with exper-
imental evidence. Nevertheless, short-lived excursions to the active state are observed.
As an experimental approach, NMR spectroscopy is an obvious choice; however efforts on several
Ser/Thr and Tyr kinases led to the general conclusion that the activation loop, including the DFG
motif and most of the active-site residues, cannot be detected due to exchange broadening, and at
Table 1. Data collection and refinement statistics for dephosphorylated Aurora A (122-403).
apo-Aurora A
(6CPE)
Aurora A + AMPPCP
(6CPF)
Aurora A + Mb + AT9283
(6CPG)
Data collection
Space group P 61 2 2 P 61 2 2 P 21 21 21
Cell dimensions
a, b, c (A˚) 80.55, 80.55, 169.79 81.75, 81.75, 172.87 63.86, 69.7, 175.56
a, b, g (˚) 90, 90, 120 90, 90, 120 90, 90, 90
Resolution (A˚) 84.90–2.45 (2.55–2.45)* 86.44–2.30 (2.39–2.30)* 43.14–2.80 (2.87–2.80)*
Rmeas 0.073 (1.308) 0.113 (2.260) 0.189 (1.268)
I/s(I) 15.0 (1.6) 10.3 (1.3) 8.9 (1.1)
CC1/2 0.998 (0.711) 0.997 (0.465) 0.986 (0.625)
Completeness (%) 99.9 (100) 100 (100) 99.2 (98.8)
Redundancy 7.6 (6.3) 9.7 (7.8) 5.4 (5.3)
Refinement
Resolution (A˚) 64.52–2.45 54.79–2.30 36.17–2.80
No. reflections 12617 (1224) 15756 (1527) 19556 (1845)
Rwork/Rfree 0.2151/0.2528 0.2179/0.2587 0.2792/0.3350
No. atoms
Protein 2035 2055 5122
Ligand/ion 11 32 56
Water 4 6
B factors
Protein 71.83 63.68 78.84
Ligand/ion 75.77 76.44 81.05
Water 52.52 45.84
R.m.s. deviations
Bond lengths (A˚) 0.005 0.004 0.003
Bond angles (˚) 0.98 0.97 0.98
The number of crystals for each structure is one for apo-Aurora A and Aurora A + AMPPCP and two crystals for Aurora A + Mb + AT9283.
*Values in parentheses are for highest-resolution shell.
DOI: https://doi.org/10.7554/eLife.36656.004
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best can only be seen after binding of drugs that stabilize conformations (Campos-Olivas et al.,
2011; Langer et al., 2004; Vajpai et al., 2008; Vogtherr et al., 2006).
[1H-15N]-TROSY-HSQC experiments on uniformly 15N-labeled samples of Aurora A proved to be
no exception: many peaks are missing and only three out of four tryptophan side chain indole signals
are seen in the 2D spectra of a [15N]-Trp labeled sample (Figure 2A,B). Therefore, we sought a strat-
egy to overcome this general problem of exchange broadening that hampers the detection of the
DFG equilibrium. Aurora A was produced containing 5-fluoro-tryptophan residues to allow for one-
dimensional 19F spectroscopy to deal with exchange broadening while providing sensitivity close to
proton NMR (Kitevski-LeBlanc and Prosser, 2012). Now, we observe as expected four peaks in our
NMR spectra for apo- and AMPPCP-bound wild-type Aurora A (Figure 2C). A deconvolution of the
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Figure 2. NMR spectra indicate extensive dynamics of the DFG-loop. (A) The four tryptophan residues in Aurora A are shown on the structure (PDB
4C3R [Zorba et al., 2014]) in stick representation; Trp277 in the DFGW-loop is highlighted in red. (B) Overlay of [1H-15N]-TROSY-HSQC spectra of
dephosphorylated Aurora A in its apo-state (U-[15N], blue; [15N]-Trp, green) and AMPPCP-bound (U-[15N], red). Only three instead of the four expected
cross peaks for tryptophan side chains are detected. (C) 19F NMR spectra of 5-fluoro-Trp labeled dephosphorylated wild-type Aurora A (apo in blue
and AMPPCP-bound in red) and the W277L Aurora A mutant bound to AMPPCP (green). The assignment of Trp277 following the DFG-loop is shown.
(D) 19F spectrum of wild-type Aurora A bound to AMPPCP (red) together with its deconvolution into four Lorentzian line shapes, the overall fit is shown
as a black, dotted line. The integrals for all four signals are equal, but the linewidth for Trp277 (purple) is approximately 5-fold larger.
DOI: https://doi.org/10.7554/eLife.36656.005
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 6 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
spectrum yields almost identical integral values for all four peaks, whereas the linewidth of one reso-
nance is approximately 5-fold larger (Figure 2D, purple signal). This broad peak is a prime candidate
to originate from Trp277, directly adjacent to the DFG-loop. The W277L mutation confirmed our
hypothesis (Figure 2C), and the extensive line broadening of this signal in a one-dimensional spec-
trum is consistent with its absence in the [1H,15N]-TROSY-HSQC spectrum. Of note, the W277L
mutant is still active, as confirmed by a kinase assay, most likely because this Trp is not conserved in
Ser/Thr kinases, where a Leu residue is found at that position for several Ser/Thr family members.
Mutating any of the other, more conserved Trp residues resulted in insoluble proteins. The broad
line shape for the Trp277 peak hints at severe exchange broadening in the surrounding of the DFG-
loop and is consistent with the high B-factors for Trp277 and its neighboring residues observed in all
crystal structures described here. Determination of relative populations and rate constants of inter-
conversion is not possible from this data, but this missing piece of information was obtained by
stopped-flow kinetics of drug binding.
Gleevec binding to Aurora A distinguishes conformational selection
versus induced-fit mechanisms
Through groundbreaking experiments on the Tyr kinases Abl and Src, the concept of drug selectivity
based on the DFG-loop conformation has received considerable attention in kinase drug discovery
(Lovera et al., 2012; Treiber and Shah, 2013). A recent report provides kinetic evidence for such
conformational selection, but identifies an induced-fit step after drug binding as the overwhelming
contribution for Gleevec selectivity towards Abl compared to Src (Agafonov et al., 2014). Here, we
ask the obvious question if this mechanism of Gleevec binding to Abl might exemplify a more gen-
eral mechanism for kinase inhibitors.
To assess which kinetic steps control drug affinity and selectivity, we first studied the binding
kinetics for Gleevec to Aurora A by stopped-flow spectroscopy using intrinsic tryptophan fluores-
cence under degassing conditions to reduce photobleaching. At 25˚C, the binding of Gleevec to
Aurora A was too fast to be monitored and, therefore, experiments were performed at 10˚C. Bind-
ing kinetics of Gleevec to Aurora A exhibited biphasic kinetic traces (Figure 3A). The first, fast phase
is characterized by a decrease in the fluorescence intensity (Figure 3A,B), with an observed rate con-
stant, kobs, increasing linearly with Gleevec concentration (Figure 3C). The slope corresponds to the
bimolecular rate constant, k2 = 1.1 ± 0.3 mM
 1s 1, of Gleevec binding to Aurora A and the dissocia-
tion of Gleevec is determined from the intercept, k 2 = 31 ± 2 s
 1 (Figure 3C). We note that the
parameters for the physical binding step are comparable to the ones obtained for Gleevec binding
to Abl (cf. k2 = 1.5 ± 0.1 mM
 1s 1 and k 2 = 25 ± 6 s
 1, measured at 5˚C) (Agafonov et al., 2014).
The second, slow phase exhibits an increase in fluorescence intensity (Figure 3A), with the observed
rate constant decreasing with Gleevec concentration (Figure 3D). The decreasing kobs provides
unequivocal evidence of conformational selection, where its rate of interconversion is slower than
the rate of ligand dissociation (k1 þ k 1  k 2). The values of k1 and k 1 can be estimated by fitting
the data to Equation 1 and are 0.014 ± 0.001 s 1 and 0.011 ± 0.002 s 1, respectively (Figure 3D).
These rate constants represent the conformational change from DFG-in to -out and vice versa since
Gleevec is a DFG-out selective inhibitor due to steric hindrance (Nagar et al., 2002;
Schindler et al., 2000; Seeliger et al., 2007).
In order to more rigorously analyze the data and test the model, all time courses of the fluores-
cence changes were globally fit using the microscopic rate constants determined above as starting
values (Figure 4) to the model in Figure 3G, where also the resulting microscopic rate constants are
given. The lack of a conformational transition after drug binding (i.e., induced-fit step) in Aurora A
should dramatically decrease drug affinity in comparison to Abl. Indeed, Gleevec binds to Aurora A
with a KD of 24 ± 7 mM (Figure 3F) compared to the low nM affinity to Abl (Agafonov et al., 2014).
Two pieces of independent evidence establish that there is indeed no induced-fit step in Gleevec
binding to Aurora A: (i) the calculated KD from the kinetic scheme is in agreement with the macro-
scopically measured KD (cf. Figure 3G and F), and (ii) the observed koff from the dilution experiment
(Figure 3E) coincides with the physical dissociation rate (i.e., intercept of the binding plot, 31 ± 2
s 1, in Figure 3C). In summary, the lack of an induced-fit step for Gleevec binding to Aurora A is the
major reason for Gleevec’s weak binding, and not the DFG-loop conformation or physical drug-bind-
ing step, consistent with our earlier results (Wilson et al., 2015).
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Kinetics of Danusertib binding to Aurora A: three-step kinetics with
conformational selection and an induced-fit step
Next, we wanted to shed light on why Danusertib, unlike Gleevec, binds very tightly to Aurora A. A
high-resolution X-ray structure shows Danusertib bound to Aurora A’s active site with its DFG-loop
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mixing 0.5 mM Aurora A with 4.5 mM Gleevec is double exponential with a fast decrease and a slow increase in fluorescence signal. (B) The decrease in
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Equation 1 and yields k1 = 0.014 ± 0.001 s
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in the out conformation (Figure 5A) (Fancelli et al., 2006), and to rationalize Danusertib’s high affin-
ity we measured the kinetics of Danusertib binding to Aurora A directly by stopped-flow experi-
ments at 25˚C. An increase in fluorescence intensity was observed at all Danusertib concentrations
and showed double-exponential behavior (Figure 5B). The dependence of the two observed rates
constants on drug concentration is linear for one of them (Figure 5C) and non-linear for the other
with an apparent plateau at approximately 16 ± 2 s 1 (Figure 5D). The step with linear inhibitor con-
centration dependence corresponds to the second-order binding step, whereas a non-linear concen-
tration dependency hints at protein conformational transitions. For a hyperbolic increase of the
observed rate with substrate concentrations, one cannot a priori differentiate between a conforma-
tional selection and an induced fit mechanism. However, conformational selection happens before
drug binding, and the intrinsic slow DFG-in to DFG-out interconversion in Aurora A revealed by
Gleevec binding (Figure 3) must, therefore, be unaltered. Since the apparent rate of 16 ± 2 s 1
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Figure 4. Global fits of Gleevec binding- and dissociation-kinetics to Aurora A at 10˚C. Fitting of kinetic traces (average, n > 5) of the mixing of 0.5 mM
Aurora A with different Gleevec concentrations at two timescales, 0.25 and 120 s, and dissociation kinetics (koff ) were performed using the KinTek
Explorer software with the binding scheme in Figure 3G. Red lines show the results of the global fit to the experimental data in black.
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Figure 5. Mechanism of Danusertib binding to Aurora A at 25˚C. (A) Danusertib bound to the DFG-out conformation of Aurora A is shown highlighting
important active-site residues in stick representation (PDB 2J50 [Fancelli et al., 2006]). (B) The increase in fluorescence upon Danusertib binding is
fitted to a double exponential. (C) Plot of kobs;Binding versus the concentration of Danusertib for the fast phase yields k2 = 0.4 ± 0.1 mM
 1s 1 and k 2 = 4.6
± 3 s 1 and the kobs;IF for the slow phase (D) reaches a plateau around 16 ± 2 s
 1. (E) Dissociation of Danusertib from Aurora A at 25˚C after a 30-fold
dilution of the Aurora A/Danusertib complex measured by Trp-fluorescence quenching and fitting with single exponential gives a value of k 3 = (3.2 ±
0.3)  10 4 s 1. (F) Double-jump experiment (2 s incubation time of 1 mM Danusertib to Aurora A followed by 60 s long dissociation step initiated by a
wash with buffer) was measured by Creoptix WAVE waveguide interferometry to properly define the value of k 2 = 6.8 ± 0.4 s
 1. (G) Macroscopic
dissociation constant (KD) determined by Creoptix WAVE waveguide interferometry: surface-immobilized Aurora A was incubated with various
concentrations of Danusertib (0.1 nM (black), 0.2 nM (blue), 0.4 nM (purple), 0.8 nM (red), 2.4 nM (green), 7.2 nM (pink), 21.6 nM (cyan), and 64.8 nM
(orange)) and surface mass accumulation was observed until establishment of equilibrium. (H) A plot of the final equilibrium value versus Danusertib
concentration yields a KD = 1.1 ± 0.4 nM. (I) Binding scheme of Danusertib (labeled D) highlighting a three-step binding mechanism, containing both
conformational selection and induced-fit step. Red lines in (B, F) and black line in (E) are the results from fitting. Kinetic constants shown in I determined
from global fitting (Figure 6). Fluorescence traces are the average of at least five replicate measurements (n > 5), and error bars and uncertainties given
in C-E, H, and I denote the (propagated) standard deviation in the fitted parameter.
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The following figure supplements are available for figure 5:
Figure supplement 1. Additional kinetic experiments to corroborate the three-state binding mechanism for Danusertib to Aurora A.
Figure 5 continued on next page
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(Figure 5D) is two orders of magnitude faster, it can only reflect an induced-fit step (i.e.,
kobs ¼ k3 þ k 3).
So, what happened to the conformational selection step? We hypothesize that the lack of this
step in our kinetic traces is due to a too small amplitude of this phase, or not observable because of
photobleaching having a bigger effect at the longer measurement times. To lessen potential photo-
bleaching, we reduced the enzyme concentration and increased the temperature to 35˚C. Indeed,
under these conditions, the slow DFG-in to DFG-out kinetics were observed as an increase of fluo-
rescence intensity over time with an observed rate constant of approximately 0.1 s 1 (Figure 5—fig-
ure supplement 1A).
While these experiments clearly establish the three-step binding mechanism, it does not provide
accurate rate constants for the conformational selection step and it cannot be observed at 25˚C
where all the other kinetic experiments are performed. To resolve this issue, we repeated the Aurora
A–Gleevec experiment at 25˚C (Figure 5—figure supplement 2A,B) and obtained reliable rate con-
stants (k1 = 0.09 ± 0.01 s
 1 and k 1 = 0.06 ± 0.005 s
 1) for the conformational selection step in
Aurora A, which will be used as ‘knowns’ in what follows. We hypothesize that the conformational
selection step reflects the interconversion between inactive/active conformations and is correlated
with the DFG-out and -in position (Figure 1). The following observations support our hypothesis: (i)
two crystal structures for the apo-protein show Trp277 in very different environments (Figure 1E), (ii)
Danusertib has been proposed to selectively bind to the DFG-out conformation based on a co-crys-
tal structure (Figure 5A) (Fancelli et al., 2006), and (iii) the same slow step is observed for binding
of both Gleevec and Danusertib.
Next, the dissociation kinetics for Danusertib was measured by fluorescence and appeared to be
extremely slow with an observed slow-off rate of (3.2 ± 0.3)  10 4 s 1 (Figure 5E). Rationalization
of complex binding kinetics cannot be done anymore by visual inspection and kinetic intuition, which
can, in fact, be misleading. In order to elucidate the correct binding mechanism and obtain accurate
kinetic parameters, all kinetic traces were globally fit (Figure 6) to the three-step binding scheme
(Figure 5I). Although global fitting of the binding and dissociation kinetics in KinTek Explorer deliv-
ered a value for k 2, evaluation of the kinetic scheme with respect to the time traces exposes that
k 2 is not well determined from our experiments. We therefore designed a double-jump experiment
to populate the AurAout:D state followed by dissociation to obtain more accurate information on
k 2. Our stopped-flow machine lacks the capability to perform double mixing and, therefore, the
double-jump experiment was performed using a Creoptix WAVE instrument. This label-free method-
ology uses waveguide interferometry to detect refractive index changes due to alteration in surface
mass in a vein similar to Surface Plasmon Resonance (SPR). It is an orthogonal technique that side-
steps notable issues associated with fluorescence methods (e.g., photobleaching and inner-filter
effects). In short, after immobilizing Aurora A on a WAVEchip, a high concentration of Danusertib
was injected for a short, variable period of time, and dissociation was triggered by flowing buffer
through the microfluidics channel to remove the drug. The dissociation kinetics fit to a single expo-
nent with a rate constant, k 2, of 6.8 ± 0.4 s
 1 (Figure 5F and Figure 5—figure supplement 1B).
We want to discuss a few additional kinetic features. First, the observed rate constant measured
in the dilution experiment (Figure 5E, k 3 = (3.2 ± 0.3)  10
 4 s 1) is slower than k 3 from the global
fit (k 3 = (7.1 ± 0.5)  10
 4 s 1), which might seem counterintuitive. The observed rate constant was
verified by an additional dilution experiment using Creoptix WAVE (k 3 = (2.0 ± 0.6)  10
 4 s 1, Fig-
ure 5—figure supplement 1C). The difference in the observed and microscopic rate constant can,
however, be fully reconciled by considering the kinetic partitioning for the proposed scheme, as
shown in Figure 6—figure supplement 1. Second, a powerful and independent validation of the
three-step binding mechanism is obtained by comparing the measured overall KD of Danusertib with
the calculated macroscopic KD from the microscopic rate constants (Figure 5G,H,I and Figure 5—
figure supplement 1D) according to Equation 4, which indeed delivers values that are within
Figure 5 continued
DOI: https://doi.org/10.7554/eLife.36656.009
Figure supplement 2. Kinetics of Gleevec binding to Aurora A at 25˚C to determine DFG-in/DFG-out equilibrium in apo Aurora A.
DOI: https://doi.org/10.7554/eLife.36656.010
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experimental error. In addition, our values for k2, k 3, and KD are in good agreement with those
reported in a recent study using SPR (Willemsen-Seegers et al., 2017).
Our results illuminate trivial but profound principles of binding affinity and lifetime of drug/target
complexes: a conformational selection mechanism always weakens the overall inhibitor affinity, while
an induced-fit step tightens the affinity depending on how far-shifted the equilibrium in the enzyme/
drug complex is (Equations 2–4, Figure 6—figure supplement 2). For DFG-out binders (e.g., Danu-
sertib and Gleevec), the DFG-in and -out equilibrium weakens the overall affinity 1.6-fold; however,
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Figure 6. Global fits of Danusertib binding and dissociation kinetics to Aurora A at 25˚C. Binding kinetics was monitored by stopped-flow fluorescence
for different concentrations of Danusertib (indicated) to 0.5 mM Aurora A, and dissociation kinetics (kobsoff ) by Creoptix and fluorimeter (see Figure 5).
Fluorescence traces are the average of at least five replicate measurements (n > 5). Global fitting was performed using the KinTek Explorer software
using the model shown in Figure 5I.
DOI: https://doi.org/10.7554/eLife.36656.011
The following figure supplements are available for figure 6:
Figure supplement 1. Kinetic partitioning of Aurora A with Danusertib.
DOI: https://doi.org/10.7554/eLife.36656.012
Figure supplement 2. Effect of the equilibrium constant for the conformational selection and induced-fit step on the overall KD for Danusertib.
DOI: https://doi.org/10.7554/eLife.36656.013
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the conformational change after drug binding results in a four orders of magnitude tighter binding
for Danusertib and is the sole reason for its high affinity to Aurora A compared to Gleevec. The dis-
sociation constants for the bimolecular binding step K2 is very similar for both inhibitors. Finally, the
lifetime of Danusertib on the target is very long because of the very slow conformational dynamics
within the Aurora A/Danusertib complex (k 3 = (7.1 ± 0.5)  10
 4 s 1). Earlier examples of protein
kinases that also show remarkable slow off-rates, presumably caused by conformational changes,
include the epidermal growth factor receptors (Berezov et al., 2001; Wood et al., 2004) and CDK8
(Schneider et al., 2013) amongst others (Willemsen-Seegers et al., 2017). To the best of our
knowledge, we present here for the first time a detailed stopped-flow kinetics analysis for Aurora A
that unequivocally shows the slow off-rate is caused by the conformational change within the drug-
bound state, and not the dissociation step.
Kinetics of AT9283 binding to Aurora A – a surprise
We chose AT9283 as a third inhibitor to characterize the binding mechanism because it has been
described as a DFG-in binder based on a crystal structure of AT9283 bound to Aurora A (PDB
2W1G, [Howard et al., 2009]). We, therefore, anticipated that in its binding kinetics one can now
detect the DFG-out to DFG-in switch. Rapid kinetic experiments of binding AT9283 to Aurora A at
25˚C resulted in biphasic traces and both processes showed an increase in fluorescence over time
(Figure 7A). The kobs for the faster phase (k2) was linearly dependent on drug concentration reflect-
ing the binding step (Figure 7B) and kobs for the slower phase (k3) has a limiting value of 0.8 ± 0.2
s 1 and is attributed to an induced-fit step (Figure 7C). For the conformational selection step (i.e.,
DFG-out to DFG-in), a decrease in fluorescence is expected because for the reverse flip observed in
the Gleevec and Danusertib experiments, a fluorescence increase was seen (Figure 3A and Fig-
ure 5—figure supplement 1A). However, we could not find any condition (e.g., by varying tempera-
ture and ligand concentrations) where such a phase could be observed.
Dissociation is characterized by double-exponential kinetics (Figure 7D and Figure 7—figure
supplement 1A). The fast phase (~38% of the total amplitude change) decays with a rate constant
of (1.1 ± 0.02)  10 2 s 1, and the slow phase (~62% of the total change in amplitude) has a rate
constant of (0.1 ± 0.01)  10 2 s 1. To distinguish between the reverse induced-fit step (k 3) and the
physical dissociation step (k 2), a double-jump experiment was performed that unambiguously
assigned the faster phase to k 2 (Figure 7E and Figure 7—figure supplement 1B). Our attempts
to globally fit all kinetic traces assuming binding to only the DFG-in state and using the rate con-
stants for the DFG-loop flip from the Gleevec experiment failed (Figure 8—figure supplement 1A).
An extended model, where AT9283 can bind to both DFGin/out conformations, followed by a com-
mon induced-fit step can also not explain the experimental kinetic traces (Figure 8—figure supple-
ment 1B). These failures, together with the lack of a detectable conformational selection step, led to
a new model in which both the DFG-in and DFG-out states can bind AT9283, but only AurAin:AT can
undergo an induced-fit step (Figure 7H). All data can be globally fit to this model (Figure 8) and the
overall KD calculated from the corresponding microscopic rate constants (using Equation 5) is in
good agreement with the experimentally measured KD (Figure 7F–H). Finally, the 10-fold difference
between the k 3 from the global fit (Figure 7H) and the experimentally observed slow off-rate can
be reconciled by kinetic partitioning as shown in Figure 7—figure supplement 1A.
Crystal structures of AT9283 bound to Aurora A buttress new binding
model
In an effort to structurally verify our model we solved a crystal structure of Aurora A with AT9283
bound and indeed observed the DFG-out conformation (PDB 6CPG, Figure 9B and Table 1), in con-
trast to the DFG-in conformation as previously reported (Figure 9A) (Howard et al., 2009). Our
structure was obtained by co-crystalizing Aurora A with AT9283 and a monobody that binds to the
same site as the natural allosteric activator TPX2 (Figure 9B). Binding of this monobody shifts Aurora
A into an inactive conformation, with the DFG-loop in the out conformation. This new structure
underscores the plasticity of Aurora A kinase and the ability of AT9283 to bind to a DFG-out state,
in addition to the previously reported DFG-in state.
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Figure 7. Mechanism of AT9283 drug binding to Aurora A at 25˚C. (A) The increase in fluorescence at 25˚C upon AT9283 binding fitted to a double
exponential. (B) The plot of kobs;Binding versus AT9283 concentration for the fast phase yields k2 = 3.4 ± 0.5 mM
 1s 1 and an underdetermined intercept
(k 2) and (C) the kobs of the slow phase reaches a plateau around 0.8 ± 0.2 s
 1. (D) Dilution of the Aurora A/AT9283 complex formed after 1 hour of
incubation. The slow dissociation was measured by Creoptix WAVE waveguide interferometry and fitted with a double exponential with rate constants
of (1.1 ± 0.02)  10 2 s 1 and (0.1 ± 0.01)  10 2 s 1. (E) Double-jump experiments (1 s incubation time of 1 mM AT9283 to Aurora A followed by 60 s
long dissociation step initiated by a wash with buffer) was measured by Creoptix WAVE waveguide interferometry to properly define the value of k 2 =
(1.0 ± 0.1) x 10 2 s 1. (F) Macroscopic dissociation constant (KD) determined by Creoptix WAVE waveguide interferometry: surface-immobilized Aurora
A was incubated with various concentration of AT9283 (0.03 nM (black), 0.27 nM (blue), 0.8 nM (purple), 2.4 nM (green), 7.2 nM (red), 21.6 nM (cyan), and
64.8 nM (orange)) and surface mass accumulation was observed until establishment of equilibrium. (G) A plot of the final equilibrium value versus
AT9283 concentration yields a KD = 2.1 ± 1.8 nM. (H) Binding scheme for AT9283 (labeled AT) highlighting a four-steps binding mechanism, that
contains binding to two different states, a conformational selection mechanism and an induced-fit step. Kinetic constants shown in H were determined
from global fitting (see Figure 8). Fluorescence traces are the average of at least five replicate measurements (n > 5), and error bars and uncertainties
given in B, C, G and H denote the (propagated) standard deviation in the fitted parameter.
DOI: https://doi.org/10.7554/eLife.36656.014
The following figure supplement is available for figure 7:
Figure supplement 1. Kinetic partitioning of Aurora A with AT9283.
DOI: https://doi.org/10.7554/eLife.36656.015
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Figure 8. Global fits of AT9283 binding and dissociation kinetics to Aurora A at 25˚C. Binding kinetics was monitored by stopped-flow fluorescence at
different concentrations of AT9283 (indicated) to 0.5 mM Aurora A. Dissociation kinetics were obtained for fully equilibrated drug/kinase complex (kobsoff )
or for the initial encounter complex (kdjumpoff ) by using a 1 hour or a short 2 s incubation of the kinase with AT9283, respectively, before inducing
dissociation by a buffer wash using Creoptix WAVE waveguide interferometry. Global fitting was performed with KinTek Explorer software using the
model in Figure 7H (reduced c2 = 3.2). Fluorescence traces are the average of at least five replicate measurements (n > 5).
DOI: https://doi.org/10.7554/eLife.36656.016
The following figure supplement is available for figure 8:
Figure supplement 1. Alternative binding models of AT9283 to Aurora A cannot explain the experimental data.
DOI: https://doi.org/10.7554/eLife.36656.017
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Thus, our structural and kinetic data together support that AT9283 can bind to both DFG-in and
DFG-out state of Aurora A, and emphasizes the need for caution when interpreting single X-ray
structures.
Inhibitors take advantage of built-in dynamics for ATP binding
We finally compared the binding kinetics of the ATP-competitive inhibitors described above with the
natural kinase substrate, ATP (Figure 10). In order to measure stopped-flow kinetics for ATP bind-
ing, FRET was measured by exciting Trp residues in Aurora A and detecting fluorescence transfer to
the ATP-analogue mant-ATP (Lemaire et al., 2006; Ni et al., 2000). The binding of mant-ATP to
Aurora A showed biphasic kinetic traces (Figure 10A) that describe the physical binding step (i.e.,
linear dependence on mant-ATP concentration; Figure 10B) and the induced-fit step (Figure 10C).
The observed rate constant approaches a maximum value defined by the sum of k3 þ k 3
(Figure 10C) and the intercept can be estimated to be k 3 and is consistent with the value obtained
from the kof f experiment (Figure 10D). We find that mant-ATP can bind to both the DFG-in and -out
conformations, consistent with our nucleotide-bound crystal structures (Figure 1A–D) and recent sin-
gle-molecule fluorescence spectroscopy data that indicates that nucleotide binding does not signifi-
cantly affect this equilibrium (Cyphers et al., 2017). To confirm the model, the kinetic data were
globally fit to a two-step binding mechanism (Figure 10G,H). The calculated KD from the
A
B
AT9283 K162
E181
D274
F275
DFG
in
-loop
AT9283 K162
F275
E181
D274
DFG
out
-loop
Mb
Mb
Figure 9. X-ray structures of Aurora A bound to inhibitor AT9283 reveal multiple binding modes. (A) AT9283 (pink) bound to the active site of Aurora A
(PDB 2W1G, [Howard et al., 2009]) shows the DFGin-loop conformation and a salt bridge between K162 and E181. (B) Aurora A dimer (light and dark
blue ribbon) in complex with AT9283 (pink) and inhibiting monobody (Mb, grey), showing DFGout-loop and broken K162 and E181 salt bridge (PDB
6CPG).
DOI: https://doi.org/10.7554/eLife.36656.018
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Figure 10. Mechanism of ATP binding to Aurora A at 10˚C. (A) Binding of mant-ATP to Aurora A was followed by an increase in fluorescence with
biphasic kinetics. The plot of kobs versus concentration of mant-ATP of the fast phase (B) yields k2 = 0.8 ± 0.2 mM
 1s 1 and k 2 = 50 ± 8 s
 1 and the slow
phase (C) reached a plateau around 21 ± 1 s 1 (k3 þ k 3 ). (D) Dissociation kinetics of 10 mM Aurora A/10 mM mant-ATP complex was measured after a
11-fold dilution into buffer and yields kobsoff = 17.2 ± 1 s
 1. (E, F) Macroscopic dissociation constant of Aurora A with mant-ATP measured by fluorescence
energy transfer. (E) Emission spectra (excitation at 290 nm) of 1 mM Aurora A (green), 160 mM mant-ATP (red), and 1 mM Aurora A/160 mM mant-ATP
(blue). (F) The change in fluorescence at 450 nm (DF450) versus mant-ATP concentrations yields KD = 22 ± 6 mM. (G) Global fitting (red) of all kinetics
data (black) in KinTek Explorer to the binding scheme shown in (H) results in the kinetic constants given in the scheme and an overall KD = 48 ± 8 mM,
calculated from all rate constants. Fluorescence traces are the average of at least five replicate measurements (n > 5), and error bars and uncertainties
given in B, C, D, F, and H denote the (propagated) standard deviation in the fitted parameter.
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corresponding microscopic rate constants (Figure 10H) is comparable with the experimental macro-
scopic KD obtained from a titration experiment (Figure 10E,F).
The presence of an induced-fit step for the natural substrate ATP suggests that such conforma-
tional change after ligand binding is a built-in property of the enzyme. In other words, inhibitors
take advantage of the inherent plasticity of the enzyme that is required for its activity and regulation.
The main difference between ATP and inhibitor binding is the rate constant for the reverse induced-
fit step (k 3). In the case of ATP, this rate is much faster and, therefore, does not significantly
increase the overall affinity. Faster conformational changes and weaker binding are of course prereq-
uisites for efficient turnover; whereas slow conformational changes, particularly the reverse induced-
fit step, are at the heart of action for an efficient drug, because it results in tight binding and a long
lifetime on the target. In summary, binding of different ligands to the ATP-binding site, such as
nucleotides or ATP-competitive inhibitors, is comprised of the physical binding step followed by an
induced-fit step. By definition, it is the nature of the induced-fit step that varies for the different
ligands since it happens as a result of ligand binding.
Discussion
Characterizing the detailed kinetic mechanisms of drug binding is not just an academic exercise but
delivers fundamental knowledge for developing selective inhibitors with high affinity. An induced-fit
step turns out to be key for all tight-binding inhibitors studied. From our results on Aurora A kinase
presented here and earlier data on Tyrosine-kinases (Agafonov et al., 2014; Wilson et al., 2015),
we propose that this may be a general mechanism for different kinases and multiple inhibitors,
thereby providing a platform for future computational and experimental efforts in rational drug
design. Albeit, we note that verification of this proposition requires a larger sampling of small mole-
cules and different protein kinases throughout the kinome.
The ‘use’ of a highly-skewed equilibrium towards E*:D for a promising drug is logical for the fol-
lowing reasons: (i) it increases the affinity for the drug by this coupled equilibrium, (ii) it prolongs the
residence time of the drug on the target due to the often slow reverse rate, (iii) it is specific for each
drug as it happens after the drug binding, and (iv) it can add selectivity for the targets because it
likely involves residues more remote from the active site. An increased drug residence time has sig-
nificant pharmacological advantages as it can lead to a prolonged biological effect, a decrease of
side effects, and a lower risk of metabolic drug modification. Such inhibitors have long been
described as slow tight-binding inhibitors (Copeland, 2016; Copeland et al., 2006). The concept of
the advantageous roles of induced-fit steps is based on simple thermodynamics and protein flexibil-
ity, and is, therefore, likely of relevance for drug design to other targets outside of the kinome.
Additionally, our data provides unique insight into the extensively discussed DFG flip. Combining
X-ray crystallography, NMR spectroscopy and stopped-flow kinetics of drug binding establish the
nature of this DFG flip both structurally, thermodynamically and kinetically, and resolves the long-
standing question of its role for drug affinity and selectivity. Selective binding of a specific DFG-state
by Gleevec has been first proposed as the reason for selectivity towards Abl. This conformational
selection principle has ever since been at the center of drug discovery for many kinases, including
Aurora A (Badrinarayan and Sastry, 2014; Liu and Gray, 2006). Based on our results, we argue
that conformational selection of the DFG-state by ATP-competitive inhibitors is a mistakenly pursued
concept in drug design for the following reasons: (i) conformational selection by definition weakens
the overall ligand affinity, (ii) active site binders are automatically inhibitors, therefore selective bind-
ing to a specific DFG-state has no advantage (Badrinarayan and Sastry, 2014; Liu and Gray, 2006),
(iii) kinases interconvert between both states. High selectivity gained by DFG-state selective binding
could only be achieved in the scenario of a highly skewed population towards the binding-compe-
tent state for one kinase relative to all others, which is unfounded.
Our results exemplify why rational drug design is so challenging. The characterization of the com-
plete free-energy landscape of drug binding is needed, which will require more sophisticated
computational approaches guided by experimental data such as provided in our study. A good illus-
tration of this point are the computational reports that focused on the DFG flip as a key determinant
drug selectivity (Badrinarayan and Sastry, 2014) that now have been ruled out by our kinetic meas-
urements. Our data suggest that future design efforts should be focusing on understanding and
exploiting induced-fit steps. To this end, the different dynamic personalities of kinases or, more
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 18 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
general, drug targets need to be investigated at atomic resolution and used to guide small-molecule
design. The findings presented here are encouraging for developing selective inhibitors even for kin-
ases with very similar folds and drug binding pockets since the action does not happen on a single
structural element of the protein, but on a complex energy landscape that is unique to each kinase.
Materials and methods
Cloning, expression and purification of dephosphorylated Aurora A
(122-403) and inhibiting monobody
Dephosphorylated Aurora A proteins were expressed and purified as described before
(Zorba et al., 2014) and analyzed by mass spectrometry to confirm their phosphorylation state. The
W227L mutant was generated using the QuickChange Lightning site-directed mutagenesis kit
(Agilent).
U-[15N] Aurora A was obtained by growing E. coli BL21(DE3) (New England Biolabs) in M9 mini-
mal medium containing 1 g/L 15NH4Cl (Cambridge Isotope Laboratories, Tewksbury, MA, USA) and
5 g/L D-glucose as the sole nitrogen and carbon source, respectively. [15N]-Trp labeled wild-type
Aurora A was obtained using the standard M9 minimal medium, complemented with all amino acids
(0.5 g/L) with the exception of tryptophan. One hour prior to induction, 30 mg/L of 15N2-L-Trp
(NLM-800; Cambridge Isotope Laboratories, Tewksbury, MA, USA) was added to the medium. Simi-
larly, to obtain samples of wild-type and W277L Aurora A containing 5-fluoro-tryptophan, bacterial
growth was performed in unlabeled M9 medium containing all amino acids (0.5 g/L) except for tryp-
tophan. One hour before protein induction, the medium was supplemented with 30 mg/L of 5-flu-
oro-DL-tryptophan (Sigma-Aldrich) (Crowley et al., 2012). NMR samples contained 200–300 mM
Aurora A in 50 mM HEPES, pH 7.3, 50 mM NaCl, 20 mM MgCl2, 5 mM TCEP, 2 M TMAO and 10%
(v/v) D2O.
Inhibiting monobody used for co-crystallization with Aurora A and AT9283 was expressed in E.
coli BL21(DE3) cells harboring the plasmid pHBT containing His6-tagged-Mb. A culture of TB media
containing 50 mg/mL kanamycin that was grown overnight at 37˚C was added to 1 L of TB media
with 50 mg/mL kanamycin to get a starting OD600 of ~0.2. This culture was grown at 37˚C until the
OD600 reached ~0.8. Protein expression was induced by 0.6 mM IPTG at 18˚C for 13–15 h and cells
were harvested by centrifugation. The cell pellet was resuspended in binding buffer (50 mM Tris-
HCl, pH 8.0, 300 mM NaCl, 20 mM imidazole, 20 mM MgCl2, 10% glycerol) containing 0.5 mg/mL
lysozyme, 5 mg/mL DNase, and 1x EDTA-free protease inhibitor cocktail. Cells were ruptured by son-
ication on ice then centrifuged at 18,000 rpm at 4˚C for 1 h. The supernatant was loaded onto His-
TrapTM HP (GE Healthcare) after filtration using 0.2 mm filtering unit. The pellet was resuspended
with GuHCl buffer (20 mM Tris-HCl, pH 8.0, 6 M GuHCl) and allowed to rotate on wheel for 10 min
at 4˚C and spun down again. The supernatant was passed through 0.2 mm filtering unit and loaded
onto HisTrap HP column previously loaded with soluble fraction and pre-equilibrated with GuHCl
buffer. Refolding monobody on-column was achieved by washing the HisTrap HP column with five
column volumes (CV) of GuHCl buffer, followed by 5 CV of Triton-X buffer (binding buffer + 0.1%
Triton X-100), then 5 CV of b-cyclodextrin buffer (binding buffer + 5 mM b-cyclodextrin), and finally
5 CV of binding buffer. Monobody was eluted with 100% of elution buffer (binding buffer + 500 mM
imidazole). The protein was dialyzed overnight in gel-filtration buffer (20 mM Tris-HCl, pH 7.5, 200
mM NaCl, 20 mM MgCl2, 5 mM TCEP, 10% glycerol) in the presence of TEV protease (1:40 TEVP:
Mb molar ratio). After dialysis, the TEV-cleaved monobody was passed through HisTrap HP column
again. The flow-through containing TEV-cleaved monobody was collected and concentrated before
loading onto Superdex 200 26/60 gel-filtration column pre-equilibrated with the gel-filtration buffer.
The monobody was flash-frozen and stored in  80˚C until use.
X-ray crystallography
Crystals of dephosphorylated (deP) Aurora A122 403 + AMPPCP were obtained by mixing 570 mM
(18 mg/mL) deP Aurora A122 403 and 1 mM AMPPCP in a 2:1 ratio with mother liquor (0.2 M ammo-
nium sulfate, 0.2 M Tris-HCl, pH 7.50, 30% (w/v) PEG-3350). The crystals were grown at 18˚C by
vapor diffusion using the hanging-drop method. The protein used for the crystallization was in stor-
age buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10% (v/v) glycerol, 20 mM MgCl2, 1 mM TCEP);
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AMPPCP was freshly prepared before use in the same buffer. Crystals were flash-frozen in liquid
nitrogen prior to shipping. Crystals of apo, deP Aurora A122 403 were grown at 18˚C by vapor diffu-
sion using the sitting-drop method (96-well plate). A 1:1 ratio of protein to mother liquor was
obtained by combining 0.5 mL of 300 mM (10 mg/mL) deP Aurora A122 403 in 50 mM HEPES, pH 7.3,
500 mM ammonium acetate, 1 mM MgCl2, 5 mM TCEP) with 0.5 mL of 0.15 M Tris-HCl, pH 7.5, 0.15
M ammonium sulfate, 35% (w/v) PEG-3350. Crystals were soaked for 10–20 s in cryo buffer (20% (w/
v) PEG-400, 20% ethylene glycol, 10% water and 50% mother liquor) before flash-freezing in liquid
nitrogen. The complex between Aurora A122 403, inhibiting monobody (Mb) and AT9283 was crystal-
lized at 18˚C by vapor diffusion using the sitting-drop method. In short, a 1:1 ratio of protein mixture
to mother liquor was obtained by combining 0.5 mL of sample [240 mM deP Aurora A122 403 + 1.0
mM AT9283 + 250 mM Mb] with 0.5 mL of mother liquor [0.1 M Bis-Tris, pH 5.5, 0.2 M magnesium
chloride, 19% (w/v) PEG-3350]. Crystals were soaked for 10–20 s in cryo buffer (17.5% (w/v) PEG-
400, 17.5% ethylene glycol, 45% water and 20% mother liquor) before flash-freezing in liquid
nitrogen.
Diffraction data were collected at 100 K at the Advanced Light Source (Lawrence Berkeley
National Laboratory) beamlines ALS 8.2.1 (apo-AurA and AurA + Mb + AT9283) and 8.2.2 (AurA +
AMPPCP) with a collection wavelength of 1.00 A˚.
Data were indexed and integrated using iMOSFLM (Battye et al., 2011) for apo/AMPPCP-bound
Aurora A and Xia2 (Winter, 2010) using XDS (Kabsch, 2010) for the Aurora A/Mb/AT9283 complex,
respectively. Data were scaled and merged with AIMLESS (Evans and Murshudov, 2013), in the
case of Aurora A/Mb/AT9283 two data separate data sets were merged. All software was used
within the CCP4 software suite (Winn et al., 2011).
As initial search models 1MQ4 (Nowakowski et al., 2002) and 3K2M (Wojcik et al., 2010) were
used for Aurora A and monobody, respectively, and molecular replacement was performed using
Phaser (McCoy et al., 2007). The molecules were placed in the unit cell using the ACHESYM web-
server (Kowiel et al., 2014). Iterative refinements were carried out with PHENIX (Adams et al.,
2010), using rosetta.refine (DiMaio et al., 2013) and phenix.refine (Afonine et al., 2012), and man-
ual rebuilding was performed in Coot (Emsley and Cowtan, 2004; Emsley et al., 2010).
Structure validation was performed using MolProbity (Chen et al., 2010) and yielded the statistics
given below. The Ramachandran statistics for dephosphorylated apo (AMPPCP-bound) Aurora A
are: favored: 93.65 (94.90)%, allowed 5.95 (4.71)%, outliers: 0.4 (0.39)%; 0.48 (0.0)% rotamer outliers
and an all-atom clashscore of 4.45 (2.44). For the Aurora A/Mb/AT9283 complex, the Ramachandran
statistics are: favored: 92.64%, allowed 7.06%, outliers: 0.3%; 0.0% rotamer outliers and an all-atom
clashscore of 2.81. We note that the B-factors for the monobodies in the complex of Aurora A/Mb/
AT9283 are rather high, indicating significantly flexibility in the parts that are not part of the binding
interface with Aurora A.
The data collection and refinement statistics are given in Table 1. Structure factors and refined
models have been deposited in the PDB under accession codes: 6CPE (apo Aurora A), 6CPF (Aurora
A + AMPPCP) and 6CPG (Aurora A/Mb/AT9283).
All figures were generated using Chimera (Pettersen et al., 2004).
NMR spectroscopy
All 19F NMR experiments were performed at 35˚C on a Varian Unity Inova 500 MHz spectrometer,
equipped with a 1H/19F switchable probe tuned to fluorine (90˚ pulse width of 12 ms). All 1D 19F
spectra were recorded with a spectral width of ~60 ppm and a maximum evolution time of 0.25 s.
An interscan delay of 1.5 s was used with 5000 scans per transients, giving rise to a total acquisition
time of 2.5 h per spectrum. To remove background signal from the probe and avoid baseline distor-
tions, data acquisition was started after a ~100 ms delay (using the ‘delacq’ macro) and appropriate
shifting of the data followed by backward linear prediction was performed. The data were apodized
with an exponential filter (2.5 Hz line broadening) and zero-filled before Fourier transform. To
improve the signal-to-noise ratio several data sets were recorded consecutively and, provided that
the sample remained stable, added together after processing (two for apo Aurora A, four for Aurora
A + AMPPCP, and five for W277L + AMPPCP, respectively). 19F chemical shifts were referenced
externally to trifluoroacetic acid (TFA) at  76.55 ppm.
[1H-15N]-TROSY-HSQC experiments were recorded at 25˚C on an Agilent DD2 600 MHz four-
channel spectrometer equipped with a triple-resonance cryogenically cooled probe-head. Typically,
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115–128 (15N)  512 (1H) complex points, with maximum evolution times equal to 48.5–64
(15N)  64 (1H) ms. An interscan delay of 1.0 s was used along with 32 or 56 scans per transient, giv-
ing rise to a net acquisition time 1.5–2.5 h for each experiment. To improve the signal-to-noise ratio
several data sets were recorded consecutively and, provided that the sample remained stable,
added together after processing (typically three data sets per sample).
All data sets were processed with the NMRPipe/NMRDraw software package (Delaglio et al.,
1995) and 2D spectra were visualized using Sparky (Goddard, 2008). Deconvolution of the 19F spec-
tra and line shape fitting was performed using the Python package nmrglue (Helmus and Jaroniec,
2013).
Kinetics experiments of Aurora A with Gleevec, Danusertib, and
AT9283
Stopped-flow experiments
Intrinsic tryptophan fluorescence spectroscopy was used to monitor drug binding kinetics to Aurora
A. All experiments were performed at 25˚C, except for the Gleevec kinetics that were measured at
10˚C (unless otherwise stated) because the binding of Gleevec to Aurora A is too fast, kobs;Binding.
Stock solutions of 200 mM Danusertib, 200 mM AT9283 and 50 mM Gleevec (all purchased from
Selleck Chemicals, http://www.selleckchem.com) were prepared in 100% DMSO were and stored at
 80˚C until used. Aurora A used in the kinetic experiments was dephosphorylated Aurora A as
determined by mass spectrometry, Western blot and activity experiments (data not shown). The
rapid kinetics were studied using a stopped-flow spectrophotometer (SX20 series from Applied Pho-
tophysics Ltd). The flow system was made anaerobic by rinsing with degassed buffer comprised of
50 mM HEPES, 50 mM NaCl, 20 mM MgCl2, 5 mM TCEP, 5% DMSO, pH 7.30 to minimize photo-
bleaching. The stock solutions of Aurora A and all drugs were made anaerobic by degassing with
ThermoVac (MicroCal) at the desired temperature. In general, a solution of 5 mM Aurora A was
loaded in one syringe and quickly mixed with drug, prepared in the same buffer, in the other syringe
(mixing ratio 1:10). A significant increase or decrease in the fluorescence intensity of Aurora A (exci-
tation at 295 nm, emission cut-off at 320 nm) can be observed due to the drug binding. For each
drug concentration, at least five replicate measurements were made and these transients were aver-
aged. Analysis was performed by fitting the individual trace to exponential equations using Pro-Data
Viewer (Applied Photophysics Ltd) or with Kinesyst 3 software (TgK Scientific) and error bars denote
the standard errors as obtained from the fit. KaleidaGraph version 4.5.3 (Synergy) was used for data
analysis and plotting. All kinetic data were globally fitted in KinTek Explorer software
(Johnson, 2009b, 2009a).
Under the rapid equilibrium approximation, the binding and dissociation steps of Gleevec to
Aurora A are fast compared to conformational selection, therefore the value of k1 and k 1 can be
estimated according to Equation 1:
kobs ¼
k 1
1þ Gleevec½ 
Aurora A½ þ
k 2
k2
 
0
@
1
A
þ k1 (1)
where k1 and k 1 represent the conformational change from DFG-in to -out and vice versa, respec-
tively. The approximate values of k1 and k 1 obtained from fitting to this equation are used as start-
ing values for the global fit.
For the 5 mM Aurora A/Gleevec complex, the release of the drug was recorded after a 11-fold
dilution of the complex using the stopped-flow instrument for 0.25 s (excitation at 295 nm, emission
cut-off at 320 nm) at 10˚C.
Creoptix WAVE experiments
Double jump, slow-off, and macroscopic KD experiments of Aurora A with drugs were studied using
a Creoptix WAVE instrument (Creoptix AG, Wa¨denswil, Switzerland) at 25˚C. All chemicals were pur-
chased from GE Healthcare, unless otherwise stated. The protocols in the WAVE control software
for conditioning of the chip, immobilization of proteins and performing kinetics experiments were
followed. In short, the polycarboxylate chip (PCH) was activated by injection of a 1:1 mixture with
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final concentrations of 200 mM N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide (EDC) and 50 mM
N-hydroxysuccinimide (NHS), followed by streptavidin immobilization (50 mg/mL in 10 mM sodium
acetate pH 5.0). Unreacted sites on the chip were blocked with 1 M ethanolamine pH 8.0. For all
activation, immobilization and passivation steps 0.2x HBS-EP was used as running buffer with a flow-
rate of 10 mL/min and an injection duration of 420 s on both channels 1 and 2.
Biotinylated T288V variant that mimics dephosphorylated Aurora A was used for experiments per-
formed on the Creoptix WAVE instrument. The activity of T288V with substrate Lats2, the macro-
scopic KD and slow-off rate of Danusertib were the same as wild-type (data not shown). Biotinylated
T288V Aurora A (70 mg/mL) was immobilized on the PCH-streptavidin chip with 10 mL/min injection
and 15 s injection duration over channel 1 only (channel 2 was used as reference channel). All experi-
ments were run in 50 mM HEPES, 50 mM NaCl, 20 mM MgCl2, 5 mM TCEP, 0.03 mg/mL BSA,
0.005% Tween-20, pH 7.30 as running buffer. Binding experiments were evaluated over a range of
Danusertib (0.13–66.67 nM), AT9283 (0.03–64.8 nM), and Gleevec (0.37–40 mM) concentrations.
Gleevec binding experiments contained 5% DMSO in the running buffer (see above) to enhance
Gleevec’s solubility. Double-jump experiments of Aurora A/drugs were performed by injecting 1 mM
Danusertib or AT9283 with 0.2, 0.4, 0.8, and 2 s injection duration for Danusertib and 1 and 3 s injec-
tion duration for AT9283 followed by a 60 s dissociation duration per injection. The slow-off experi-
ments were performed by injecting 5 mM Danusertib or AT9283 with 5–10 s injection duration (to
fully saturate Aurora A) followed by a 180 s injection of buffer to remove the excess drug and the
dissociation was measured for a duration of 10800 s.
Spectrofluorometer experiments
The spectrofluorometer FluoroMax-4 (Horiba Scientific) with temperature controller was used to
study the slow-off rate of Aurora A with Danusertib at 25˚C. For this experiment, a solution contain-
ing 30 nM Aurora A and 30 nM Danusertib was pre-incubated for an hour, before diluting 30-fold
into degassed buffer (ratio 1:30). A significant decrease in the fluorescence intensity of Aurora A
(excitation at 295 nm, emission at 340 nm) can be seen due to the Danusertib release. The fluores-
cence signal was recorded every 160 s for a duration of six hours using the photobleaching minimiza-
tion option that will close the shutter after each acquisition. A control experiment was performed,
using the same experimental conditions, but without drug in order to account for photobleaching.
Overall dissociation constant calculated from intrinsic rate constants
In the following equations, K1, K2, K3 and K4 are equal to:
K1 ¼
k 1
k1
K2 ¼
k 2
k2
¼
koff
kon
K3 ¼
k 3
k3
K4 ¼
k 4
k4
Conformational selection followed by inhibitor binding:
Ein
k 1
*)
k1
Eout þ I
koff
*)
kon
Eout  I
K1 K2 KD ¼ ðK1þ 1Þ K2
(2)
Inhibitor binding followed by an induced-fit step:
Eoutþ I
koff
*)
kon
Eout  I
k 3
*)
k3
E
out
 I
K2 K3 KD ¼
K2K3
ðK3þ1Þ
(3)
Conformational selection followed by inhibitor binding and an induced-fit step:
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Ein
k 1
*)
k1
Eoutþ I
koff
*)
kon
Eout  I
k 3
*)
k3
E
out
 I
K1 K2 K3 KD ¼
ðK1þ1ÞK2K3
K3þ1
(4)
Conformational selection mechanism, followed by inhibitor binding to both DFG-in and -out
state, but an induced-fit step only occurs in the DFG-in state:
Eout
k 1
*)
k1
Einþ I
koff
*)
kon
Ein  I
k 3
*)
k3
E
in
 I
K4
( +
Eout I
K1 K2 K3 KD ¼
ðK1þ1ÞK2K3K4
K1K2K3þK3K4þK4
(5)
The uncertainties in the calculated dissociation constant parameter using the equations above are
obtained using standard error propagation.
Aurora A binding to mant-ATP
FRET using intrinsic tryptophan fluorescence is used to monitor mant-ATP (obtained from Jena Bio-
science) binding kinetics to Aurora A at 10˚C. In the binding experiment or kon, increasing concentra-
tion of mant-ATP were quickly mixed to 0.5 mM Aurora A (ratio 1:10, excitation at 295 nm, emission
cut-off at 395 nm). In the experiment to measure the release of mant-ATP or koff , 10 mM/10 mM
Aurora A/mant-ATP complex was diluted with buffer (ratio 1:10). A significant decrease in the fluo-
rescence intensity of Aurora A (excitation at 295 nm, emission cut-off at 395 nm) can be seen due to
the mant-ATP release.
Macroscopic dissociation constant experiments
Fluorescence titration experiments were measured using FluoroMax-4 spectrofluorometer (Horiba
Scientific). Increasing amounts of Aurora A/Danusertib complex (4 nM Aurora A and 150 nM Danu-
sertib) or Aurora A/mant-ATP (1 mM Aurora A and 2 mM mant-ATP) were titrated into an Aurora A
solution (4 nM and 1 mM Aurora A for experiments with Danusertib and mant-ATP, respectively). To
measure Danusertib affinity, the excitation wavelength was 295 nm (5 nm bandwidth) and emission
spectra were recorded from 310 to 450 nm (20 nm bandwidth) in increments of 2 nm and the tem-
perature was maintained at 25˚C. For the mant-ATP experiment, the dissociation constant was mea-
sured at 10˚C using fluorescence energy transfer from tryptophan residues in Aurora A to mant-ATP
by setting the excitation wavelength to 290 nm (5 nm bandwidth) and collecting the emission inten-
sity from 310 to 550 nm (5 nm bandwidth) in increments of 2 nm. A control experiment in the
absence of Aurora A was performed using the same experimental settings and used to correct for
the mant-ATP interference. In all experiments, a 5 min equilibration time was used after each addi-
tion of Aurora A/Danusertib complex or Aurora A/mant-ATP complex.
The fluorescence intensity at 368 nm versus Danusertib concentration or the change in fluores-
cence at 450 nm (DF450) versus mant-ATP concentration was fitted to Equation 6 using Levenberg-
Marquardt nonlinear fitting algorithm included in KaleidaGraph to obtain the KD.
F ¼ F0þA 
I½  þ Et½ þKD 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
I½  þ Et½ þKDð Þ
2 4  Et½   I½ 
q
2  Et½ 
(6)
F and F0 are the fluorescence and initial fluorescence intensities, respectively. I½  and Et½  are the
total concentration of the drug or mant-ATP and the Aurora A, respectively.
Acknowledgements
We thank C. Sassetti (University of Massachusetts Medical School, Worcester) for the use of the ESI-
Q-TOF instrument, and the Advanced Light Source (ALS), Berkeley, CA, USA, for access to beam-
lines BL8.2.1. and BL8.2.2. The Berkeley Center for Structural Biology is supported in part by the
National Institutes of Health, National Institute of General Medical Sciences, and the HHMI. The ALS
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 23 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Depart-
ment of Energy under contract DE-AC02-05CH11231. We thank Shohei and Akiko Koide (New York
University) for the plasmid of the monody used here. This work was supported by the Howard
Hughes Medical Institute (HHMI); the Office of Basic Energy Sciences, Catalysis Science Program, U.
S. Dept. of Energy (award DE-FG02-05ER15699); and the NIH (grant GM100966-01). R.O. was a
HHMI Fellow of the Damon Runyon Cancer Research Foundation (DRG-2114–12).
Additional information
Funding
Funder Grant reference number Author
Howard Hughes Medical Insti-
tute
Dorothee Kern
National Institutes of Health GM100966-01 Dorothee Kern
U.S. Department of Energy DE-FG02-05ER15699 Dorothee Kern
Damon Runyon Cancer Re-
search Foundation
DRG-2114-12 Renee Otten
The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Warintra Pitsawong, Conceptualization, Formal analysis, Investigation, Visualization, Writing—origi-
nal draft, Writing—review and editing; Vanessa Buosi, Conceptualization, Formal analysis, Investiga-
tion, Visualization, Writing—original draft; Renee Otten, Conceptualization, Formal analysis, Funding
acquisition, Investigation, Visualization, Writing—original draft, Writing—review and editing; Roman
V Agafonov, Conceptualization, Formal analysis, Investigation, Visualization, Writing—review and
editing; Adelajda Zorba, Gunther Kern, Conceptualization, Formal analysis, Investigation, Writing—
review and editing; Nadja Kern, Xavier Meniche, Formal analysis, Investigation; Steffen Kutter,
Ricardo AP Pa´dua, Formal analysis, Investigation, Writing—review and editing; Dorothee Kern, Con-
ceptualization, Supervision, Funding acquisition, Writing—original draft, Project administration, Writ-
ing—review and editing
Author ORCIDs
Warintra Pitsawong http://orcid.org/0000-0001-5438-1783
Renee Otten http://orcid.org/0000-0001-7342-6131
Adelajda Zorba http://orcid.org/0000-0002-4452-8419
Nadja Kern http://orcid.org/0000-0002-1313-5890
Steffen Kutter http://orcid.org/0000-0002-0349-8161
Ricardo AP Pa´dua http://orcid.org/0000-0001-9719-3440
Dorothee Kern http://orcid.org/0000-0002-7631-8328
Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.36656.039
Author response https://doi.org/10.7554/eLife.36656.040
Additional files
Supplementary files
. Transparent reporting form
DOI: https://doi.org/10.7554/eLife.36656.020
Data availability
Diffraction data have been deposited in PDB under the accession codes 6CPE, 6CPF, 6CPG.
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 24 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
The following datasets were generated:
Author(s) Year Dataset title Dataset URL
Database, license,
and accessibility
information
Otten R, Kutter S,
Buosi V, Padua
RAP, Kern D
2018 Structure of apo,
dephosphorylated Aurora A (122-
403) in an active conformation
https://www.rcsb.org/
pdb/search/structid-
Search.do?structureId=
6CPE
Publicly available at
RCSB Protein Data
Bank (accession no:
6CPE)
Otten R, Zorba A,
Padua RAP, Kern D
2018 Structure of dephosphorylated
Aurora A (122-403) bound to
AMPPCP in an active conformation
https://www.rcsb.org/
pdb/search/structid-
Search.do?structureId=
6CPF
Publicly available at
RCSB Protein Data
Bank (accession no:
6CPF)
Otten R, Kutter S,
Zorba A, Padua
RAP, Kern D
2018 Structure of dephosphorylated
Aurora A (122-403) in complex with
inhibiting monobody and AT9283
in an inactive conformation
https://www.rcsb.org/
pdb/search/structid-
Search.do?structureId=
6CPG
Publicly available at
RCSB Protein Data
Bank (accession no:
6CPG)
The following previously published datasets were used:
Author(s) Year Dataset title Dataset URL
Database, license,
and accessibility
information
Zorba A, Kutter S,
Cho YJ, Kern D
2014 Structure of dephosphorylated
Aurora A (122-403) bound to
AMPPCP
https://www.rcsb.org/
pdb/search/structid-
Search.do?structureId=
4C3R
Publicly available at
RCSB Protein Data
Bank (accession no:
4C3R)
Cheetham GMT,
Knegtel RMA, Coll
JT, Renwick SB,
Swenson L, Weber
P, Lippke JA, Aus-
ten DA
2003 CRYSTAL STRUCTURE OF
AURORA-2, AN ONCOGENIC
SERINE-THREONINE KINASE
https://www.rcsb.org/
pdb/search/structid-
Search.do?structureId=
1MUO
Publicly available at
RCSB Protein Data
Bank (accession no:
1MUO)
Bayliss R, Conti E 2003 Structure of Human Aurora-A 122-
403 phosphorylated on Thr287,
Thr288
https://www.rcsb.org/
pdb/search/structid-
Search.do?structureId=
1OL7
Publicly available at
RCSB Protein Data
Bank (accession no:
1OL7)
Howard S, Berdini
V, Boulstridge JA,
Carr MG, Cross
DM, Curry J, De-
vine LA, Early TR,
Fazal L, Gill AL,
Heathcote M, Ma-
man S, Matthews
JE, McMenamin RL,
Navarro EF,
O’Brien MA, O’Re-
illy M, Rees DC,
Reule M, Tisi D,
Williams G, Vinko-
vic M, Wyatt PG
2009 Structure determination of Aurora
Kinase in complex with inhibitor
https://www.rcsb.org/
pdb/search/structid-
Search.do?structureId=
2W1G
Publicly available at
RCSB Protein Data
Bank (accession no:
2W1G)
Cameron AD, Izzo
G, Storici P, Rus-
coni L, Fancelli D,
Varasi M, Berta D,
Bindi S, Forte B,
Severino D, Tonani
R, Vianello P
2006 Structure of Aurora-2 in complex
with PHA-739358
https://www.rcsb.org/
pdb/search/structid-
Search.do?structureId=
2J50
Publicly available at
RCSB Protein Data
Bank (accession no:
2J50)
References
Adams PD, Afonine PV, Bunko´czi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-
Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC,
Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta
Crystallographica Section D Biological Crystallography 66:213–221. DOI: https://doi.org/10.1107/
S0907444909052925, PMID: 20124702
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 25 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, Terwilliger TC,
Urzhumtsev A, Zwart PH, Adams PD. 2012. Towards automated crystallographic structure refinement with
phenix.refine. Acta Crystallographica Section D Biological Crystallography 68:352–367. DOI: https://doi.org/10.
1107/S0907444912001308, PMID: 22505256
Agafonov RV, Wilson C, Otten R, Buosi V, Kern D. 2014. Energetic dissection of gleevec’s selectivity toward
human tyrosine kinases. Nature Structural & Molecular Biology 21:848–853. DOI: https://doi.org/10.1038/
nsmb.2891, PMID: 25218445
Asteriti IA, Daidone F, Colotti G, Rinaldo S, Lavia P, Guarguaglini G, Paiardini A. 2017. Identification of small
molecule inhibitors of the Aurora-A/TPX2 complex. Oncotarget 8:32117–32133. DOI: https://doi.org/10.18632/
oncotarget.16738, PMID: 28389630
Badrinarayan P, Sastry GN. 2014. Specificity rendering ’hot-spots’ for aurora kinase inhibitor design: the role of
non-covalent interactions and conformational transitions. PLoS ONE 9:e113773. DOI: https://doi.org/10.1371/
journal.pone.0113773, PMID: 25485544
Barakat KH, Huzil JT, Jordan KE, Evangelinos C, Houghton M, Tuszynski J. 2013. A computational model for
overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant. Molecular
Pharmaceutics 10:4572–4589. DOI: https://doi.org/10.1021/mp4003893, PMID: 24094068
Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG. 2011. iMOSFLM: a new graphical interface for
diffraction-image processing with MOSFLM. Acta Crystallographica. Section D, Biological Crystallography 67:
271–281. DOI: https://doi.org/10.1107/S0907444910048675, PMID: 21460445
Bavetsias V, Linardopoulos S. 2015. Aurora kinase inhibitors: current status and outlook. Frontiers in Oncology 5:
278. DOI: https://doi.org/10.3389/fonc.2015.00278, PMID: 26734566
Bavetsias V, Pe´rez-Fuertes Y, McIntyre PJ, Atrash B, Kosmopoulou M, O’Fee L, Burke R, Sun C, Faisal A, Bush K,
Avery S, Henley A, Raynaud FI, Linardopoulos S, Bayliss R, Blagg J. 2015. 7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]
pyridine-based derivatives for kinase inhibition: co-crystallisation studies with Aurora-A reveal distinct
differences in the orientation of the pyrazole N1-substituent. Bioorganic & Medicinal Chemistry Letters 25:
4203–4209. DOI: https://doi.org/10.1016/j.bmcl.2015.08.003, PMID: 26296477
Bayliss R, Burgess SG, McIntyre PJ. 2017. Switching Aurora-A kinase on and off at an allosteric site. The FEBS
Journal 284:2947–2954. DOI: https://doi.org/10.1111/febs.14069, PMID: 28342286
Bayliss R, Sardon T, Vernos I, Conti E. 2003. Structural basis of Aurora-A activation by TPX2 at the mitotic
spindle. Molecular Cell 12:851–862. DOI: https://doi.org/10.1016/S1097-2765(03)00392-7, PMID: 14580337
Berezov A, Zhang HT, Greene MI, Murali R. 2001. Disabling erbB receptors with rationally designed exocyclic
mimetics of antibodies: structure-function analysis. Journal of Medicinal Chemistry 44:2565–2574. DOI: https://
doi.org/10.1021/jm000527m, PMID: 11472210
Borisa AC, Bhatt HG. 2017. A comprehensive review on Aurora kinase: small molecule inhibitors and clinical trial
studies. European Journal of Medicinal Chemistry 140:1–19. DOI: https://doi.org/10.1016/j.ejmech.2017.08.
045, PMID: 28918096
Burgess SG, Oleksy A, Cavazza T, Richards MW, Vernos I, Matthews D, Bayliss R. 2016. Allosteric inhibition of
Aurora-A kinase by a synthetic vNAR domain. Open Biology 6:160089. DOI: https://doi.org/10.1098/rsob.
160089, PMID: 27411893
Campos-Olivas R, Marenchino M, Scapozza L, Gervasio FL. 2011. Backbone assignment of the tyrosine kinase src
catalytic domain in complex with imatinib. Biomolecular NMR Assignments 5:221–224. DOI: https://doi.org/10.
1007/s12104-011-9304-7, PMID: 21523440
Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello
P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E,
et al. 2007. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant
to cancer. Molecular Cancer Therapeutics 6:3158–3168. DOI: https://doi.org/10.1158/1535-7163.MCT-07-0444,
PMID: 18089710
Carvajal RD, Tse A, Schwartz GK. 2006. Aurora kinases: new targets for Cancer therapy. Clinical Cancer Research
12:6869–6875. DOI: https://doi.org/10.1158/1078-0432.CCR-06-1405, PMID: 17145803
Cheetham GM, Knegtel RM, Coll JT, Renwick SB, Swenson L, Weber P, Lippke JA, Austen DA. 2002. Crystal
structure of aurora-2, an oncogenic serine/threonine kinase. Journal of Biological Chemistry 277:42419–42422.
DOI: https://doi.org/10.1074/jbc.C200426200, PMID: 12237287
Chen C, Ha BH, The´venin AF, Lou HJ, Zhang R, Yip KY, Peterson JR, Gerstein M, Kim PM, Filippakopoulos P,
Knapp S, Boggon TJ, Turk BE. 2014. Identification of a major determinant for serine-threonine kinase
phosphoacceptor specificity. Molecular Cell 53:140–147. DOI: https://doi.org/10.1016/j.molcel.2013.11.013,
PMID: 24374310
Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson
DC. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallographica
Section D Biological Crystallography 66:12–21. DOI: https://doi.org/10.1107/S0907444909042073,
PMID: 20057044
Cohen P. 2002. Protein kinases–the major drug targets of the twenty-first century? Nature Reviews Drug
Discovery 1:309–315. DOI: https://doi.org/10.1038/nrd773, PMID: 12120282
Copeland RA, Pompliano DL, Meek TD. 2006. Drug-target residence time and its implications for lead
optimization. Nature Reviews Drug Discovery 5:730–739. DOI: https://doi.org/10.1038/nrd2082, PMID: 16
888652
Copeland RA. 2016. The drug-target residence time model: a 10-year retrospective. Nature Reviews Drug
Discovery 15:87–95. DOI: https://doi.org/10.1038/nrd.2015.18, PMID: 26678621
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 26 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
Crowley PB, Kyne C, Monteith WB. 2012. Simple and inexpensive incorporation of 19F-Tryptophan for protein
NMR spectroscopy. Chemical Communications 48:10681–10683. DOI: https://doi.org/10.1039/c2cc35347d
Cyphers S, Ruff EF, Behr JM, Chodera JD, Levinson NM. 2017. A water-mediated allosteric network governs
activation of Aurora kinase A. Nature Chemical Biology 13:402–408. DOI: https://doi.org/10.1038/nchembio.
2296, PMID: 28166210
Dar AC, Lopez MS, Shokat KM. 2008. Small molecule recognition of c-Src via the Imatinib-binding conformation.
Chemistry & Biology 15:1015–1022. DOI: https://doi.org/10.1016/j.chembiol.2008.09.007, PMID: 18940662
Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: a multidimensional spectral
processing system based on UNIX pipes. Journal of Biomolecular NMR 6:277–293. DOI: https://doi.org/10.
1007/BF00197809, PMID: 8520220
DiMaio F, Echols N, Headd JJ, Terwilliger TC, Adams PD, Baker D. 2013. Improved low-resolution
crystallographic refinement with Phenix and rosetta. Nature Methods 10:1102–1104. DOI: https://doi.org/10.
1038/nmeth.2648, PMID: 24076763
Dodson CA, Kosmopoulou M, Richards MW, Atrash B, Bavetsias V, Blagg J, Bayliss R. 2010. Crystal structure of
an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design.
Biochemical Journal 427:19–28. DOI: https://doi.org/10.1042/BJ20091530, PMID: 20067443
Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallographica. Section D,
Biological Crystallography 60:2126–2132. DOI: https://doi.org/10.1107/S0907444904019158, PMID: 15572765
Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of coot. Acta Crystallographica.
Section D, Biological Crystallography 66:486–501. DOI: https://doi.org/10.1107/S0907444910007493,
PMID: 20383002
Evans PR, Murshudov GN. 2013. How good are my data and what is the resolution? Acta Crystallographica
Section D Biological Crystallography 69:1204–1214. DOI: https://doi.org/10.1107/S0907444913000061,
PMID: 23793146
Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P,
Croci W, Forte B, Giorgini ML, Klapwijk J, Marsiglio A, Pesenti E, Rocchetti M, Roletto F, Severino D, et al.
2006. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a
favorable antitumor kinase inhibition profile. Journal of Medicinal Chemistry 49:7247–7251. DOI: https://doi.
org/10.1021/jm060897w, PMID: 17125279
Ferguson FM, Doctor ZM, Chaikuad A, Sim T, Kim ND, Knapp S, Gray NS. 2017. Characterization of a highly
selective inhibitor of the Aurora kinases. Bioorganic & Medicinal Chemistry Letters 27:4405–4408. DOI: https://
doi.org/10.1016/j.bmcl.2017.08.016, PMID: 28818446
Fraedrich K, Schrader J, Ittrich H, Keller G, Gontarewicz A, Matzat V, Kromminga A, Pace A, Moll J, Bla¨ker M,
Lohse AW, Ho¨rsch D, Bru¨mmendorf TH, Benten D. 2012. Targeting aurora kinases with danusertib (PHA-
739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an
orthotopic xenograft model. Clinical Cancer Research 18:4621–4632. DOI: https://doi.org/10.1158/1078-0432.
CCR-11-2968, PMID: 22753592
Fu J, Bian M, Jiang Q, Zhang C. 2007. Roles of Aurora kinases in mitosis and tumorigenesis. Molecular Cancer
Research 5:1–10. DOI: https://doi.org/10.1158/1541-7786.MCR-06-0208, PMID: 17259342
Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. 2008. Aurora kinases as anticancer drug
targets. Clinical Cancer Research 14:1639–1648. DOI: https://doi.org/10.1158/1078-0432.CCR-07-2179,
PMID: 18347165
Gilburt JAH, Sarkar H, Sheldrake P, Blagg J, Ying L, Dodson CA. 2017. Dynamic equilibrium of the AuroraA
kinase activation loop revealed by single-molecule Spectroscopy. Angewandte Chemie International Edition 56:
11409–11414. DOI: https://doi.org/10.1002/anie.201704654, PMID: 28700101
Goddard TDK. 2008. SPARKY 3. 3.115. San Francisco, University of California.
Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK,
Hertz NT, Eilers M, Shokat KM, Weiss WA. 2014. Drugging MYCN through an allosteric transition in Aurora
kinase A. Cancer Cell 26:414–427. DOI: https://doi.org/10.1016/j.ccr.2014.07.015, PMID: 25175806
Helmus JJ, Jaroniec CP. 2013. Nmrglue: an open source Python package for the analysis of multidimensional
NMR data. Journal of Biomolecular NMR 55:355–367. DOI: https://doi.org/10.1007/s10858-013-9718-x,
PMID: 23456039
Heron NM, Anderson M, Blowers DP, Breed J, Eden JM, Green S, Hill GB, Johnson T, Jung FH, McMiken HH,
Mortlock AA, Pannifer AD, Pauptit RA, Pink J, Roberts NJ, Rowsell S. 2006. SAR and inhibitor complex
structure determination of a novel class of potent and specific aurora kinase inhibitors. Bioorganic & Medicinal
Chemistry Letters 16:1320–1323. DOI: https://doi.org/10.1016/j.bmcl.2005.11.053, PMID: 16337122
Hopkins AL, Groom CR. 2002. The druggable genome. Nature Reviews Drug Discovery 1:727–730. DOI: https://
doi.org/10.1038/nrd892, PMID: 12209152
Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL,
Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O’Brien MA, O’Reilly M, Rees DC, Reule
M, Tisi D, et al. 2009. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase
inhibitor with potent aurora kinase activity. Journal of Medicinal Chemistry 52:379–388. DOI: https://doi.org/
10.1021/jm800984v, PMID: 19143567
Iqbal N, Iqbal N. 2014. Imatinib: a breakthrough of targeted therapy in Cancer. Chemotherapy Research and
Practice 2014:1–9. DOI: https://doi.org/10.1155/2014/357027
Janecˇek M, Rossmann M, Sharma P, Emery A, Huggins DJ, Stockwell SR, Stokes JE, Tan YS, Almeida EG,
Hardwick B, Narvaez AJ, Hyvo¨nen M, Spring DR, McKenzie GJ, Venkitaraman AR. 2016. Allosteric modulation
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 27 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2. Scientific
Reports 6:28528. DOI: https://doi.org/10.1038/srep28528, PMID: 27339427
Johnson KA, Simpson ZB, Blom T. 2009a. Global kinetic explorer: a new computer program for dynamic
simulation and fitting of kinetic data. Analytical Biochemistry 387:20–29. DOI: https://doi.org/10.1016/j.ab.
2008.12.024, PMID: 19154726
Johnson KA. 2009b. Fitting enzyme kinetic data with KinTek global kinetic explorer. Methods in Enzymology
467:601–626. DOI: https://doi.org/10.1016/S0076-6879(09)67023-3, PMID: 19897109
Kabsch W. 2010. XDS. Acta Crystallographica. Section D, Biological Crystallography 66:125–132. DOI: https://
doi.org/10.1107/S0907444909047337, PMID: 20124692
Katayama H, Sen S. 2010. Aurora kinase inhibitors as anticancer molecules. Biochimica Et Biophysica Acta (BBA)
- Gene Regulatory Mechanisms 1799:829–839. DOI: https://doi.org/10.1016/j.bbagrm.2010.09.004
Kilchmann F, Marcaida MJ, Kotak S, Schick T, Boss SD, Awale M, Go¨nczy P, Reymond JL. 2016. Discovery of a
selective aurora A kinase inhibitor by virtual screening. Journal of Medicinal Chemistry 59:7188–7211.
DOI: https://doi.org/10.1021/acs.jmedchem.6b00709, PMID: 27391133
Kitevski-LeBlanc JL, Prosser RS. 2012. Current applications of 19F NMR to studies of protein structure and
dynamics. Progress in Nuclear Magnetic Resonance Spectroscopy 62:1–33. DOI: https://doi.org/10.1016/j.
pnmrs.2011.06.003, PMID: 22364614
Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M. 2012. Aurora kinase inhibitors:
progress towards the clinic. Investigational New Drugs 30:2411–2432. DOI: https://doi.org/10.1007/s10637-
012-9798-6, PMID: 22350019
Kornev AP, Taylor SS. 2010. Defining the conserved internal architecture of a protein kinase. Biochimica Et
Biophysica Acta (BBA) - Proteins and Proteomics 1804:440–444. DOI: https://doi.org/10.1016/j.bbapap.2009.
10.017
Kornev AP, Taylor SS. 2015. Dynamics-Driven allostery in protein kinases. Trends in Biochemical Sciences 40:
628–647. DOI: https://doi.org/10.1016/j.tibs.2015.09.002, PMID: 26481499
Kowiel M, Jaskolski M, Dauter Z. 2014. ACHESYM: an algorithm and server for standardized placement of
macromolecular models in the unit cell. Acta Crystallographica Section D Biological Crystallography 70:3290–
3298. DOI: https://doi.org/10.1107/S1399004714024572, PMID: 25478846
Langer T, Vogtherr M, Elshorst B, Betz M, Schieborr U, Saxena K, Schwalbe H. 2004. NMR backbone assignment
of a protein kinase catalytic domain by a combination of several approaches: application to the catalytic subunit
of cAMP-dependent protein kinase. ChemBioChem 5:1508–1516. DOI: https://doi.org/10.1002/cbic.
200400129, PMID: 15481030
Lemaire PA, Tessmer I, Craig R, Erie DA, Cole JL. 2006. Unactivated PKR exists in an open conformation capable
of binding nucleotides. Biochemistry 45:9074–9084. DOI: https://doi.org/10.1021/bi060567d, PMID: 16866353
Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, Karplus M, Cole PA, Kuriyan J. 2006. A Src-like
inactive conformation in the abl tyrosine kinase domain. PLoS Biology 4:e144. DOI: https://doi.org/10.1371/
journal.pbio.0040144, PMID: 16640460
Liu Y, Gray NS. 2006. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical
Biology 2:358–364. DOI: https://doi.org/10.1038/nchembio799, PMID: 16783341
Lok W, Klein RQ, Saif MW. 2010. Aurora kinase inhibitors as anti-cancer therapy. Anti-Cancer Drugs 21:339–350.
DOI: https://doi.org/10.1097/CAD.0b013e3283350dd1, PMID: 20016367
Lovera S, Sutto L, Boubeva R, Scapozza L, Do¨lker N, Gervasio FL. 2012. The different flexibility of c-Src and c-Abl
kinases regulates the accessibility of a druggable inactive conformation. Journal of the American Chemical
Society 134:2496–2499. DOI: https://doi.org/10.1021/ja210751t, PMID: 22280319
Lukasiewicz KB, Lingle WL. 2009. Aurora A, centrosome structure, and the centrosome cycle. Environmental and
Molecular Mutagenesis 50:602–619. DOI: https://doi.org/10.1002/em.20533, PMID: 19774610
Martin MP, Zhu JY, Lawrence HR, Pireddu R, Luo Y, Alam R, Ozcan S, Sebti SM, Lawrence NJ, Scho¨nbrunn E.
2012. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. ACS Chemical
Biology 7:698–706. DOI: https://doi.org/10.1021/cb200508b, PMID: 22248356
Marumoto T, Zhang D, Saya H. 2005. Aurora-A - a guardian of poles. Nature Reviews Cancer 5:42–50.
DOI: https://doi.org/10.1038/nrc1526, PMID: 15630414
Marzo I, Naval J. 2013. Antimitotic drugs in cancer chemotherapy: promises and pitfalls. Biochemical
Pharmacology 86:703–710. DOI: https://doi.org/10.1016/j.bcp.2013.07.010, PMID: 23886991
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic
software. Journal of Applied Crystallography 40:658–674. DOI: https://doi.org/10.1107/S0021889807021206,
PMID: 19461840
McIntyre PJ, Collins PM, Vrzal L, Birchall K, Arnold LH, Mpamhanga C, Coombs PJ, Burgess SG, Richards MW,
Winter A, Veverka V, Delft FV, Merritt A, Bayliss R. 2017. Characterization of three druggable Hot-Spots in the
Aurora-A/TPX2 interaction using biochemical, biophysical, and Fragment-Based approaches. ACS Chemical
Biology 12:2906–2914. DOI: https://doi.org/10.1021/acschembio.7b00537, PMID: 29045126
Meng Y, Lin YL, Roux B. 2015. Computational study of the "DFG-flip" conformational transition in c-Abl and
c-Src tyrosine kinases. The Journal of Physical Chemistry B 119:1443–1456. DOI: https://doi.org/10.1021/
jp511792a, PMID: 25548962
Meng Y, Pond MP, Roux B. 2017. Tyrosine kinase activation and conformational flexibility: lessons from Src-
Family tyrosine kinases. Accounts of Chemical Research 50:1193–1201. DOI: https://doi.org/10.1021/acs.
accounts.7b00012, PMID: 28426203
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 28 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. 2002. Crystal
structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib
(STI-571). Cancer Research 62:4236–4243. PMID: 12154025
Ni Q, Shaffer J, Adams JA. 2000. Insights into nucleotide binding in protein kinase A using fluorescent adenosine
derivatives. Protein Science : A Publication of the Protein Society 9:1818–1827. DOI: https://doi.org/10.1110/
ps.9.9.1818, PMID: 11045627
Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, Golemis EA. 2013. Aurora A kinase (AURKA) in normal
and pathological cell division. Cellular and Molecular Life Sciences 70:661–687. DOI: https://doi.org/10.1007/
s00018-012-1073-7, PMID: 22864622
Nowakowski J, Cronin CN, McRee DE, Knuth MW, Nelson CG, Pavletich NP, Rogers J, Sang BC, Scheibe DN,
Swanson RV, Thompson DA. 2002. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases
from nanovolume crystallography. Structure 10:1659–1667. DOI: https://doi.org/10.1016/S0969-2126(02)
00907-3, PMID: 12467573
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF chimera–a
visualization system for exploratory research and analysis. Journal of Computational Chemistry 25:1605–1612.
DOI: https://doi.org/10.1002/jcc.20084, PMID: 15264254
Ruff EF, Muretta JM, Thompson AR, Lake EW, Cyphers S, Albanese SK, Hanson SM, Behr JM, Thomas DD,
Chodera JD, Levinson NM. 2018. A dynamic mechanism for allosteric activation of Aurora kinase A by
activation loop phosphorylation. eLife 7:e32766. DOI: https://doi.org/10.7554/eLife.32766, PMID: 29465396
Sarvagalla S, Coumar MS. 2015. Structural biology insight for the design of Sub-type selective aurora kinase
inhibitors. Current Cancer Drug Targets 15:375–393. PMID: 25895501
Schindler T, BornmannW, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571
inhibition of Abelson tyrosine kinase. Science 289:1938–1942. DOI: https://doi.org/10.1126/science.289.5486.
1938, PMID: 10988075
Schneider EV, Bo¨ttcher J, Huber R, Maskos K, Neumann L. 2013. Structure-kinetic relationship study of CDK8/
CycC specific compounds. Proceedings of the National Academy of Sciences 110:8081–8086. DOI: https://doi.
org/10.1073/pnas.1305378110, PMID: 23630251
Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J. 2007. c-Src binds to the Cancer drug imatinib
with an inactive abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15:299–311.
DOI: https://doi.org/10.1016/j.str.2007.01.015, PMID: 17355866
Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. 2009. Equally potent
inhibition of c-Src and abl by compounds that recognize inactive kinase conformations. Cancer Research 69:
2384–2392. DOI: https://doi.org/10.1158/0008-5472.CAN-08-3953, PMID: 19276351
Shukla D, Meng Y, Roux B, Pande VS. 2014. Activation pathway of src kinase reveals intermediate states as
targets for drug design. Nature Communications 5:3397. DOI: https://doi.org/10.1038/ncomms4397,
PMID: 24584478
Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, van Noort C, Mariani M, Spinelli R,
Carpinelli P, Laffranchi B, de Jonge MJ. 2009. Phase I pharmacokinetic and pharmacodynamic study of the
aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. Journal of Clinical
Oncology 27:5094–5101. DOI: https://doi.org/10.1200/JCO.2008.21.6655, PMID: 19770380
Taylor SS, Keshwani MM, Steichen JM, Kornev AP. 2012. Evolution of the eukaryotic protein kinases as dynamic
molecular switches. Philosophical Transactions of the Royal Society B: Biological Sciences 367:2517–2528.
DOI: https://doi.org/10.1098/rstb.2012.0054
Treiber DK, Shah NP. 2013. Ins and outs of kinase DFG motifs. Chemistry & Biology 20:745–746. DOI: https://
doi.org/10.1016/j.chembiol.2013.06.001, PMID: 23790484
Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, Grzesiek S, Jahnke W. 2008. Solution
conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different
binding modes of imatinib/nilotinib and dasatinib. Journal of Biological Chemistry 283:18292–18302.
DOI: https://doi.org/10.1074/jbc.M801337200, PMID: 18434310
Vogtherr M, Saxena K, Hoelder S, Grimme S, Betz M, Schieborr U, Pescatore B, Robin M, Delarbre L, Langer T,
Wendt KU, Schwalbe H. 2006. NMR characterization of kinase p38 dynamics in free and ligand-bound forms.
Angewandte Chemie International Edition 45:993–997. DOI: https://doi.org/10.1002/anie.200502770,
PMID: 16374788
Willemsen-Seegers N, Uitdehaag JCM, Prinsen MBW, de Vetter JRF, de Man J, Sawa M, Kawase Y, Buijsman
RC, Zaman GJR. 2017. Compound selectivity and target residence time of kinase inhibitors studied with surface
plasmon resonance. Journal of Molecular Biology 429:574–586. DOI: https://doi.org/10.1016/j.jmb.2016.12.
019, PMID: 28043854
Wilson C, Agafonov RV, Hoemberger M, Kutter S, Zorba A, Halpin J, Buosi V, Otten R, Waterman D, Theobald
DL, Kern D. 2015. Kinase dynamics. using ancient protein kinases to unravel a modern Cancer drug’s
mechanism. Science 347:882–886. DOI: https://doi.org/10.1126/science.aaa1823, PMID: 25700521
Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy
A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011.
Overview of the CCP4 suite and current developments. Acta Crystallographica. Section D, Biological
Crystallography 67:235–242. DOI: https://doi.org/10.1107/S0907444910045749, PMID: 21460441
Winter G. 2010. xia2 : an expert system for macromolecular crystallography data reduction . Journal of Applied
Crystallography 43:186–190. DOI: https://doi.org/10.1107/S0021889809045701
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 29 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S.
2010. A potent and highly specific FN3 monobody inhibitor of the abl SH2 domain. Nature Structural &
Molecular Biology 17:519–527. DOI: https://doi.org/10.1038/nsmb.1793, PMID: 20357770
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K,
Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L. 2004. A unique structure for epidermal growth factor
receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and
receptor activity in tumor cells. Cancer Research 64:6652–6659. DOI: https://doi.org/10.1158/0008-5472.CAN-
04-1168, PMID: 15374980
Xu W, Harrison SC, Eck MJ. 1997. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385:595–602.
DOI: https://doi.org/10.1038/385595a0, PMID: 9024657
Zhao B, Smallwood A, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, Lai Z. 2008. Modulation of kinase-
inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680
and with TPX2. Protein Science 17:1791–1797. DOI: https://doi.org/10.1110/ps.036590.108, PMID: 18662907
Zheng H, Cooper DR, Porebski PJ, Shabalin IG, Handing KB, Minor W. 2017. CheckMyMetal : a macromolecular
metal-binding validation tool . Acta Crystallographica Section D Structural Biology 73:223–233. DOI: https://
doi.org/10.1107/S2059798317001061
Zorba A, Buosi V, Kutter S, Kern N, Pontiggia F, Cho YJ, Kern D. 2014. Molecular mechanism of Aurora A kinase
autophosphorylation and its allosteric activation by TPX2. eLife 3:e02667. DOI: https://doi.org/10.7554/eLife.
02667, PMID: 24867643
Pitsawong et al. eLife 2018;7:e36656. DOI: https://doi.org/10.7554/eLife.36656 30 of 30
Research article Cancer Biology Structural Biology and Molecular Biophysics
